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ABSTRACT 
Carbon nanotubes (CNTs) have attracted significant attention as novel one-
dimensional nanomaterials due to their unique structures and properties. Aggregate 
properties of CNTs such as high surface area, length, or chemical composition are 
further tailored to enhance their potential application in nanomedicine, through 
post synthesis chemical modification procedures. These modifications 
simultaneously alter their aggregate physiochemical properties and this has a direct 
impact on cytotoxicity of CNTs in cells. A lot of research has been done towards 
the toxicity of CNTs, however, there is need for results that are consistent and 
standardized if the application of CNTs in nanomedicine is to be a reality. Indeed 
the toxicology study of CNTs has been compromised by conflicting toxicity 
results due to lack of physiochemical characterization, regulation of the synthesis 
and standardized cytotoxicity assays. Herein, the effects of the physiochemical 
characteristics of riluzole loaded CNTs on their toxicity in neuronal cells is 
evaluated to elucidate a better understanding of CNTs toxicity. Furthermore the 
cellular uptake and overall efficacy of riluzole loaded CNTs is evaluated. 
 
As prepared multiwalled carbon nanotubes (MWCNTs) synthesized by the 
Catalytic Chemical Vapor Deposition (CCVD) method were initially acid oxidized 
using strong acids at different temperature and reaction time so as to remove 
impurities whilst introducing carboxylic groups on to the surface. The drug 
riluzole was then conjugated to the oxidized MWCNTs via carbodiimide activated 
amidation. The purification and functionalization led to the isolation of 
physicochemical properties as characterized by the Transmission Electron 
Microscopy (TEM), Raman spectroscopy, BET surface area analysis and 
Thermogravimetric Analysis (TGA). These physiochemical properties i.e. length, 
surface area, degree of fictionalization and amount of chemical impurities were 
key determinants of the drug loaded MWCNTs’ cytotoxicity. 
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The data from this study supports the hypothesis that physiochemical 
modifications of MWCNTs that occur due to the functionalization of the drug to 
its surfaces alter their toxicity in neuronal systems. The riluzole loaded MWCNTs 
with <15% metallic residue, 500-2000nm length, and high surface area (30-76 
m
2
/g) were found to cross the cell membrane without causing toxic effects as all 
the cells were viable compared to the untreated cells control. Covalently linking 
riluzole to MWCNTs and the consequent changes in the physiochemical properties 
did not lead to the generation of toxic effects in cells. Furthermore chemically 
binding riluzole to the MWCNTs did not deactivate the drug and reduce its ability 
to be antiglutamate. The identification of specific physiochemical properties 
governing CNTs toxicity presents the opportunity for carbon nanotube based drug 
delivery system designs or applications that reduce human and environmental 
impacts. 
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1. INTRODUCTION 
1.1 Background and motivation 
1.1.1 Amyotrophic Lateral Sclerosis  
Amyotrophic Lateral Sclerosis (ALS) is a lethal neurodegenerative disorder 
characterized by the progressive and selective death of both upper and lower 
motor neurons (Hughes, 1982). Most ALS patients die from respiratory failure, 
usually within 3 to 5 years from the onset of symptoms although large deviations 
have been observed (Williams and Windebank, 1991). Over the years many 
pathogenic mechanisms have been proposed that cause ALS and these include 
oxidative stress (Rosen et al., 1993), mitochondrial dysfunction (Kong et al., 
1998), aggregate formation, neuro-factors deficiency (Johnston et al., 2000), and 
glutamate excitotoxicity (Henchcliffe et al., 2007). This multitude of factors 
indicate that ALS is a multifactoral disease and multisystemic making it highly 
challenging to treat as using one group of therapeutic agents will address only one 
of the pathogenic mechanisms. 
 
The annual worldwide incidence of ALS worldwide is between four and nine per 
100,000 populations (Kurtzke, 1982) with a clear male predominance 
(Haverkamp et al., 1995). The economic and social impact of this disease 
significantly affects healthcare payers (health insurance), patients and their 
families. There is loss of productivity due to temporary disability, premature 
retirement or informal care (Schepelmann et al., 2010). Cost of care increases 
with disease progression, and annual costs of ALS have been reported to be 
ranging between EUR 15,000-36,190 (USD 41,340) in Europe (Lopez-Bastida et 
al., 2009; Van Der Steen et al., 2009; Schepelmann et al., 2010). 
 
1.1.2 Riluzole 
There is no cure or standard treatment for ALS. A number of agents have been 
found to be anticonvulsant and neuroprotective towards ALS, including riluzole, 
gabapentin, symmetral, amantadine and N-acetylcysteine. However, the drug 
riluzole (Rilutek
®
) (Aventis Pharmaceuticals, NJ, USA) is the only prescribed 
drug approved by the U.S. Food and Drug Administration (FDA) to treat ALS. 
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Riluzole (6-(Trifluoromethoxy)-2-aminobenzothiazole; Figure 1.1) is a glutamate 
and glutamate receptor antagonist (Bohme et al., 1994) used as an anticonvulsant 
(Chapman, 1998).  
 
 
 
 
 
Figure 1.1 Chemical structure of riluzole ( Cheah et al., 2010) 
Riluzole prolongs life of patients with ALS by 2-3 months but does not relieve 
symptoms (Bensimon et al., 1994; Traynor et al., 2003). The moderate efficacy of 
riluzole may be due to low bioavailability, lack of multifunctionality, as it is 
primarily antiglutamic which is only one of the several ALS pathogenic routes. 
Furthermore it is insoluble in most physiological solutions and this negatively 
affects its transport in the body and the ability of the drug to be easily absorbed. 
Riluzole is approximately 90% absorbed following an oral dose but only 30-60% 
reaches the target site (Wokke, 1996). This can be explained by the fact that this 
agent primarily undergoes rapid chemical degradation into its inactive metabolites 
(e.g. riluzole-glucuronide) in the liver.  
1.1.3 Drug delivery with carbon nanotubes 
The possibility of incorporating carbon nanotubes (CNTs) into living systems has 
opened the way for the investigation of their potential application in the emerging 
field of nanomedicine. A drug delivery system is generally designed to improve 
the pharmacological and therapeutic profile of a drug molecule (Allen, 2004). 
Problems associated with the administration of free drugs, such as limited 
solubility, poor biodistribution, lack of multifunctionality, unfavorable 
pharmacokinetics, can be overcome and/or eliminated by the use of an efficient 
drug delivery system. The dispersibility, nanosize, good biodistribution, ability to 
be multi-functionalized and be target specific renders functionalized CNTs to be 
potentially novel and effective delivery vehicles. 
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Small drug molecules have been covalently conjugated to CNTs for effective non-
cytotoxic in vitro delivery. Fluorescent dyes and drug cargos were simultaneously 
linked to 1, 3-dipolar cycloaddition functionalized CNTs via amide bonds for the 
delivery of an anti-cancer drug (Pastorin et al., 2006), biomacromolecules 
including proteins, DNA and RNA (Kam et al., 2004; Pantarotto et al., 2004; Kam 
et al., 2005) or an anti-fungi drug (Wu et al., 2005) into cells. Beside covalent 
conjugation, a novel non-covalent supramolecular chemistry has been uncovered, 
for loading aromatic drug molecules to functionalized CNTs by π-π stacking 
(Singh et al., 2009). Targeting ligands including folic acid (Kam et al., 2005) and 
peptides (Liu et al., 2007) have been used to target drug loaded CNTs to specific 
types of cells in vitro or to tumors in vivo. Furthermore the hallow structure of 
CNTs has allowed the encapsulation of drug molecules inside nanotubes for drug 
delivery. Fullerene balls (Kataura et al., 2001) and even DNA molecules (Kaneko 
et al., 2007) have been encapsulated inside CNTs. 
 
Indeed, for successful ALS therapy an efficient riluzole delivery system is 
required. This will allow for an increased bioavailability and reduce the adverse 
effects which sometimes lead to discontinuation of the drug. From previous work 
it has been shown that CNTs have the capability to easily and rapidly translocate 
into cellular components in a non-invasive way (Bianco et al., 2005; Wu et al., 
2005). Drug loaded CNTs therefore present an opportunity for the enhancement of 
the cellular uptake and consequently transport and biodistribution of therapeutic 
agents without displaying cytotoxicity. 
 
1.2 Research problem 
With a multitude of opportunities for carbon nanotube use in pharmaceutical and 
medical applications, a thorough understanding of associated systemic toxicity is 
critical. Common purification and functionalisation of CNTs significantly and 
simultaneously modify their physicochemical properties such as dispersivity in 
solution, length, chemical composition and surface area. There is a correlation 
between cytotoxicity and these physicochemical properties that enhance CNTs to 
cell contact opportunities (Kang et al.,2008). 
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Past toxicity assessments have differentiated between single walled and 
multiwalled carbon nanotubes but only a few have investigated the effects of 
physical and chemical characteristic modification when reporting the toxicity 
(Tian et al., 2006; Sayes et al., 2006; Kang et al., 2008). Tian et al., (2006) 
explored the eukaryotic cytotoxicity of a wide range of carbonaceous materials 
including CNTs. Their conclusion support surface area and surface chemistry as 
primary determinants of cytotoxicity. Sayes et al.,(2006) performed in vitro 
toxicity on cultured human fibroblast cells. They showed that cytotoxic response 
of cells in culture is dependent on the degree of functionalization of the single-
walled carbon nanotube. Kang et al.,(2008) compared the toxicity of 
commercially obtained CNTs before and after physiochemical modification. They 
observed a higher bacterial toxicity when the nanotubes were uncapped, 
debundled, short and dispersed in solution. 
 
Analysis of CNT toxicity is complicated as it draws upon studies with vastly 
different synthesis technique, solution chemistry and sample purity. Material 
characterization, standardized toxicity assays and careful documentation of 
studies of the correlation between cytotoxicity and physiochemical properties of 
CNTs will be fundamental to a mechanistic understanding of nanotube toxicity 
(Kang et al., 2008). Herein, the aim is to give a detailed characterisation of the 
physical and chemical properties of sequentially modified riluzole loaded 
multiwalled carbon nanotubes (riluzole-MWCNTs) via different degrees of acid 
oxidation functionalization to support toxicity results. Each of the samples is 
derived from the same initial bulk MWCNT stock to reduce variability in sample 
purity. 
 
1.3 Problem statement 
Cell viability after treatment with drug loaded CNTs is an important issue that 
needs to be thoroughly addressed. Length, degree of functionalization, presence of 
residual metal catalyst and surface area are physiochemical characteristics which 
contribute to the toxicity of substances in cells and tissues. Functionalization of 
their surface to produce drug loaded CNTs results in changes of the 
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physiochemical characteristics of CNTs. The physicochemical modifications may 
have positive or negative impact on the biocompatibility of drug loaded CNTs in 
cells.  
 
1.4 Research questions 
In solving the research problems mentioned above the following questions must 
be answered; 
 How does the length distribution, degree of functionalization, amount of 
catalytic metal impurities and surface area vary with the conditions of acid 
treatment and functionalization? 
 Are the riluzole loaded MWCNTs dispersible hence biocompatible? 
 How does the concentration of the drug affect the conjugation rate and 
efficiencies and what is the rate law that describes the conjugation process 
of the drug to the MWCNTs? 
 Are the drug loaded carbon nanotubes able to translocate into cells? 
 What is the effect of modification of the physicochemical properties of the 
drug loaded MWCNTs that comes with functionalization on cytotoxicity? 
 Will the covalent attachment of the drug to MWCNTs alter the activity of 
the drug? 
 What further work needs to be done to maximize the benefits of 
nanotechnology? 
1.5 Expected benefits of drug-loaded carbon nanotubes 
Functionalization of MWCNT surface can result in highly soluble materials, 
which can be further derivatized with drugs, making them compatible with 
biological systems. Therefore, many biomedical applications can be envisaged. 
The rational functionalization of MWCNTs by riluzole to isolate their specific 
physical and chemical properties will give a better understanding of the cell 
viability observed when drug loaded MWCNTs interact with cells. Furthermore, 
drug-loaded MWCNTs have the following potential advantages:  
1. Their easy and rapid translocation into cellular components will enhance 
the uptake of the drugs and consequently the efficacy (Bianco et al., 2005). 
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2. The tubular structure of nanotubes represents the potential ability to help 
drugs, attached to them or inside their hollow structure to escape rapid 
deactivation and degradation in tissues and organs.  
3. Distinctive inner and outer surfaces increase surface area and the ability to 
be differentially functionalized by several different drugs. This will help 
overcome the current limitations of single drugs in the effective treatment 
of diseases such as ALS which have several pathogenic routes. 
4. Higher drug loading capacity will mean a decrease in the frequency of 
doses (Wu et al, 2005). This will help reduce hepatic toxicity of the drugs 
which results from damages to the liver with long term use of drugs. 
Furthermore there will be a reduction in health care costs as reduced dose 
frequency means less visits to the hospitals and pharmacies. 
 
1.6 Aim and objectives 
The aim of this study is to develop and characterize drug-loaded CNTs which will 
then be analyzed on its effectiveness and physicochemical effects on cells. In 
order to achieve this aim the following objectives are outlined: 
1. Synthesize Carbon nanotubes (MWCNTs) using the Catalytic Chemical 
Vapor Deposition (CCVD) synthesis route.  
2. Incorporate a drug on to the surface of the MWCNTs using 
functionalization methods. 
3. Characterize the physiochemical properties of the drug-loaded MWCNTs. 
4. In vitro conjugation efficiency studies 
5. Perform in vitro  studies on rat neuronal cell lines to: 
 Trace the capacity of the drug-loaded MWCNTs to cross the cell 
membrane 
 Determine physiochemical effects of drug-loaded MWCNTs on 
toxicity 
 Determine the efficacy of the drug-loaded MWCNTs as a 
neuroprotective agent 
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1.6.1 Research hypothesis 
The physiochemical modifications of drug-loaded MWCNTs i.e. lengths (500-
3000nm), surface areas (30-80m
2
/g) and high degrees of functionalization will 
alter their cytotoxicity in neuronal systems. The resulting drug-MWCNT 
conjugate will easily and rapidly enter into cellular components across the 
membrane in a non-invasive and non cytotoxicity manner. Furthermore 0.1-10µM 
concentrations of conjugated riluzole will be neuroprotective against glutamate 
excitotoxicity as the same concentration of free riluzole. 
 
1.7 Scope of the research work 
The scope of the research encompasses the synthesis of carbon nanotubes, 
purification of the CNTs using acid oxidation and preparation of drug-loaded 
carbon nanotubes using amidation functionalization routes. This will then be 
followed by characterisation of the physiochemical properties and evaluation of 
their effects on drug-loaded carbon nanotubes’ toxicity in neuronal cells, kinetics 
study of the conjugation process and evaluation of the anti-excitotoxicity 
properties of the drug-loaded carbon nanotubes. 
 
1.8 Organization of Dissertation 
The work is divided into five major chapters. The first chapter gives the 
background/ motivation of the research, research problem, aims and objectives, 
hypothesis and scope of the research. Chapter two starts by a brief overview of 
CNTs, type, synthesis routes, formation mechanisms, and properties of the CNTs. 
A survey of the functionalization techniques will then follow before a 
comprehensive literature survey on the application of CNTs in drug delivery and 
the toxicity considerations. Chapter three describes the research methodology and 
experimental procedures for the research. Chapter four dwells on the analysis of 
the results and discussion of results associated with the production of drug loaded 
CNTs, characterization of the physiochemical properties and their effects on 
toxicity of the drug-nanotube conjugate in cells. Chapter five presents the 
conclusions based on synthesis, functionalization, characterization, efficacy and 
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cytotoxicity outcomes. Recommendations for future work are included in the 
same chapter. Lastly the list of referenced material and appendices are given. 
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2. LITERATURE REVIEW 
2.1 Carbon nanotubes 
Carbon nanotubes (CNTs) were synthesized for the first time in 1991 by (Ijima, 
1991), while he was studying the material deposited on the cathode during the arc-
evaporation synthesis of fullerenes. He found that the central core of the cathodic 
deposit contained a variety of closed graphitic structures including nanoparticles 
and nanotubes. 
 
2.1.1 Structure of carbon nanotubes 
CNTs are well-ordered, high aspect ratio allotropes of carbon. The bonding in 
carbon nanotubes is sp², with each atom joined to three neighbours, as in graphite. 
The tubes can therefore be considered as rolled-up graphene sheets (graphene is 
an individual graphite layer) (Thostenson et al., 2001). The two main variants are 
single-walled carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes 
(MWCNTs). MWCNTs are larger and consist of many single walled tubes staked 
inside the other.          
 
Figure 2.1 Molecular structure of SWCNTs (left) and MWCNTs (right) (Hirsch, 2002) 
The structure of CNTs can be specified by a vector, (n,m), which defines how the 
graphene sheet is rolled up (Figure 2.2). Two atoms in a planar graphene sheet are 
SWCNT MWCNT 
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chosen and one is used as origin (Dresselhaus et al., 1995). The chiral vector C is 
pointed from the first atom toward the second one and is defined by the equation 
2.1  
                    C=na1+ma2                                                                                                            (2.1)  
Where: n and m are integers. a1 and a2 are the unit cell vectors of the two-
dimensional lattice formed by the graphene sheets. The direction of the CNT axis 
is perpendicular to this chiral vector. For example; to produce a CNT with the 
indices (6,3), say, the sheet is rolled up so that the atom labelled (0,0) is 
superimposed on the one labelled (6,3). It can be seen from the figure that m = 0 
for all zigzag tubes, while n = m for all armchair tubes (Figure 2.2). 
 
 
 
 
 
 
 
 
 
Figure 2.2 The 2D graphene sheet diagram showing a vector structure classification used to 
define CNT structure (Dresselhaus et al., 1996) 
 
 
2.2 Properties of carbon nanotubes 
Regardless whether they contain either one (SWCNTs) or multiple (MWCNTs) 
graphene sheets, they present several interesting properties, such as high aspect-
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ratio, ultra-light weight, tremendous strength (Yu et al., 2000), high thermal 
conductivity (Berber et al., 2000) and remarkable electronic properties ranging 
from metallic to semiconducting (Odom et al., 1998; Moradian etal., 2010). 
 
2.2.1 Size of carbon nanotubes 
CNTs vary significantly in length and diameter depending on the method of 
synthesis. Diameters range from 0.7-3nm (Jorio et al., 2001) for SWCNTs and 10-
200nm for MWCNTs. The length is typically several millimetres though this 
varies significantly. As a consequence of their small dimensions, CNTs have very 
high aspect ratios (length to diameter). The available surface area is dependent on 
length, diameter and degree of agglomeration. Theoretically, unbundled SWCNTs 
have surface areas of approx 1300m
2
/g, whereas MWCNTs have a surface area of 
a few hundred m
2
/g (Peigney et al., 2001).  
 
2.2.2 Mechanical property 
The strength of the sp² carbon-carbon bonds gives carbon nanotubes amazing 
mechanical properties. The Young's modulus of the best nanotubes can be as high 
as 1000GPa which is approximately 5x higher than steel. The tensile strength, or 
breaking strain of nanotubes can be up to 63GPa, around 50x higher than steel 
(Yu et al., 2000; Walters et al., 1999). Moreover, they align themselves into ropes 
held together by the Van der Waals forces and can merge together under high 
pressure, trading some sp
2
 bonds to sp
3
 and producing very strong wires of 
nanometric lateral dimension. These properties, coupled with the lightness of 
carbon nanotubes, give them great potential in applications such as the 
reinforcement of plastics to make stronger membranes and structures. 
 
 
2.2.3 Electrical property 
The electronic properties of carbon nanotubes are also extraordinary. Especially 
notable is the fact that nanotubes can be metallic or semiconducting depending on 
their structure (Mintmire et al., 1992; Saito et al., 1992). These authors (Mintmire 
et al., 1992; Saito et al., 1992) suggested that electronic band structure 
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calculations predict that the (n,m) indices determine the metallic or 
semiconducting behaviour of CNTs. Zigzag (n,0) CNTs should have two distinct 
types of behaviour: the tubes will be metals when n/3 is an integer, and otherwise 
semiconductors (Dresselhaus et al., 1996). There is great interest in the possibility 
of constructing nanoscale electronic devices from CNTs, and some progress is 
being made in this area. CNTs possess higher electrical conductivity than copper 
due to their low resistance and very few defects along their structure. The 
electrical resistivity of CNTs was found to be as low as 10
−6Ωm and often can be 
altered by modifying the structure of the nanotube lattice (Meyyappan, 2005). 
 
2.2.4 Thermal property 
Thermal conductivity is expected to be very high in the axial direction, but very 
low in the lateral direction. The thermal conductivity of carbon nanotubes is 
dependent on the temperature and the large phonon mean free paths. Hone et al., 
(1999) found that the thermal conductivity was temperature dependent, and was 
almost a linear relationship. They also found that the thermal conductivity for a 
single rope at room temperature could vary between 1800-6000W·m
−1
·K
−1
, 
compare this to copper, a metal well-known for its good thermal conductivity, 
which transmits 385W·m
−1
·K
−1
. Berber et al., (2000) determined the thermal 
conductivity of carbon nanotubes and its dependence on temperature. They 
confirmed the suggestion of Hone et al., (1999) by suggesting an unusually high 
value of 6,600 W·m
−1
·K
−1 
for the thermal conductivity at room temperature. They 
theorized that these high values would be due to the large phonon mean free 
paths. The properties are summarised in the Table 2.1 
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Table 2.1 Summary of the properties of CNTs 
Attribute Assessment 
Aspect ratio~3000m2/ Higher than any material 
Young modulus~1000GPa Stiffer than any other material 
Tensile strength~63Mpa 50 times the strength of steel 
Maximal supported electrical current 
density: ~10
9
A/cm2 
~100 times greater than that of copper 
wires 
Thermal conductivity~6000 W/m-K ~100 times greater than diamond 
 
2.3 Synthesis methods 
There are three methods commonly used to synthesize CNTs; arc discharge, 
chemical vapour deposition (CVD) and laser ablation. In all the above methods 
the common feature is addition of energy to a carbon source to produce groups or 
single carbon atoms that can recombine to generate carbon nanotubes. The energy 
source may be electricity from an arc discharge, heat from a furnace for CVD or 
high intensity light from a laser for laser ablation. 
 
2.3.1 Arc discharge method 
In arc discharge technique, a vapor is created by an arc discharge between two 
carbon electrodes with or without catalyst (Figure 2.3). The carbon contained in 
the negative electrode sublimates because of the high temperatures caused by the 
discharge. CNTs self-assemble from the resulting carbon vapour (Ebbesen et al., 
1992). Arc discharge methods generally produce large quantities of impure 
material. Commonly used gaseous carbon sources include: methane, ethylene, 
ethanol, carbon monoxide and acetylene. If both electrodes are pure graphite, the 
main product will be MWCNTs. If SWCNTs are preferable, the anode has to be 
doped with metal catalyst, such as iron, cobalt or nickel.  
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Figure 2.3 Schematic drawing of an arc discharge apparatus (Ebbesen et al., 1992). 
 
Tubes are easily produced (typical yields of 30–90%) and tend to be short with 
random sizes and directions. SWCNTs have diameters of 0.6–1.4nm while 
MWCNTs have inner diameter of 1–3nm and outer diameter of approximately 10 
nm. Often they need a lot of purification (Journet et al., 1998). 
 
2.3.2 Laser ablation 
In the laser ablation technique, a high power laser beam impinges on a volume of 
carbon containing feedstock gas (such as methane or carbon monoxide) causing 
carbon atoms to ablate/evaporate. A carrier gas sweeps the carbon atoms from the 
high-temperature zone (1200
o
C) to a cold copper collector on which they 
condense into carbon nanotubes (Puretzky et al., 2000). In order to generate 
SWCNTs using the laser ablation technique, it is necessary to impregnate the 
carbon source target with transition metal catalysts (Terrones and Terrones, 2003). 
Laser ablation produces a small amount of clean CNTs with typical yields of 70%. 
Furthermore it produces primarily SWCNTs which are long (5-20microns) and 
have diameters of 1-2nm (Saito et al., 1992). MWCNTs produced by this method 
have a number of layers varying from 4nm to 24nm and an inner diameter ranging 
between 1.5nm and 3.5nm (Meyyappan, 2005). 
Anode (+) Cathode (-) 
Inert gas 
Plasma 
Direct current 
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Figure 2.4 Schematic drawings of a laser ablation apparatus (Puretzky et al., 2000) 
 
Laser ablation has the advantage of good diameter control and the CNTs formed 
have very few defects. The morphology and the properties of CNTs are highly 
influenced by many different parameters such as light intensity, furnace 
temperature, type of hydrocarbon and carrier gas, and the flow rate of different 
gases (Meyyappan, 2005). For example, when the furnace temperature is below 
800
o
C no carbon nanotube growth is observed, whereas a maximum SWCNT 
yield is obtained at about 1200
o
C (Yudasaka et al., 1999; Puretzky et al., 2000). 
Unfortunately, the laser ablation technique is very costly, as it requires expensive 
lasers and high power requirement, (Terrones and Terrones, 2003). 
 
2.3.3 Chemical Vapor Deposition 
Chemical Vapor Deposition (CVD) generally involves reacting a carbon 
containing gas (such as acetylene, ethylene, and carbon dioxide) with a metal 
catalyst particle (usually cobalt, nickel, iron or a combination of these such as 
cobalt/iron or cobalt/molybdenum) at temperatures above 600
o
C (Abdulkareem et 
al., 2007; Iyuke et al., 2007).  
Argon gas 
1200
o
C furnace 
Graphite 
target 
Water cooled 
Copper collector 
Laser 
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Figure 2.5 Schematic drawings of a vertical chemical vapor deposition apparatus 
(Abdulkareem et al., 2007). 
 
As the carbon source continuously and slowly passes through the reactor at high 
temperatures, the hydrocarbon decomposes into hydrogen and carbon. The carbon 
atoms dissolve and diffuse into the metal surface and rearrange themselves into a 
network containing hexagons of carbon atoms and finally precipitate out in the 
form of CNTs. Once the metal surface is covered by amorphous carbon and its 
surface is “poisoned,” the carbon atoms cannot come into contact with the metal 
catalyst, resulting in the termination of CNT growth (Ijima and Ichihashi, 1993). 
CVD has yields ranging from 20-100% and results in long tubes with diameters 
ranging from 0.6nm to 4nm for SWCNTs and 10 to 240nm for MWCNTs. The 
CNTs are usually MWCNTs and rarely SWCNTs. There are two different CVD 
configurations used widely today: horizontal furnace and vertical furnace. The 
advantages of the CVD method are that it can be scaled up and produces high-
quality production of CNTs at a relatively low cost. In addition, the growth of 
CNTs can be controlled by adjusting the reaction parameters such as the catalyst 
system, temperature, type of hydrocarbon, and the flow rate of the gases (Iyuke et 
al., 2007). 
 
 
mixer 
Carbon source 
and inert gas 
Iron, nickel, Cobalt 
on support 
600-1000
o
C 
Furnace 
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2.4 Mechanisms of formation 
The mechanism of CNTs formation is widely debated and still needs to be 
thoroughly researched and understood. The most accepted growth mechanisms are 
two models: tip-growth (Ijima and Ichihasi, 1993) and root growth (Saito et al., 
1995). In the former, a tubule tip is open so that carbon atoms can be added to its 
circumference, and the metal catalyst promotes the growth reaction and also 
prevents the tubule tip closure. The size of the metal particle was seen to 
determine the diameter of the tubes (Hafner et al., 1998). The latter model is 
based on the phase diagram of carbon and a metal. The CNTs grow as carbon 
precipitates when the molten metal dissolving carbon is cooled and solidified. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1 Visualization of a possible CNT growth mechanism (Ijima and 
Ichihasi, 1993; Saito et al., 1995) 
 
In this work the catalytic CVD method will be used as it has the highest yield, 
simplest, cheap and the growth of CNTs can be controlled by adjusting the 
reaction parameters such as the catalyst system, temperature, type of hydrocarbon, 
and the flow rate of the gases. 
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2.5 Toxicity considerations of CNTs  
In the last few years, both SWCNTs and MWCNTs have been utilized as 
nanocarriers for parenteral drug and gene delivery and recently as targeted cancer 
treatments. The safety of CNTs is still in debate due to the lack of systematic and 
complete toxicity evaluation. Studies have implicated size (aggregation), CNT 
length, surface area and co-contaminants from synthesis as sources for potential 
toxicity (Sayes et al., 2006; Kang et al., 2008). The clearance of deposited 
particles in the body basically involves two processes, physical translocation and 
chemical dissolution. The particles eventually get adsorbed and diffuse into 
cellular spaces or into the blood and lymphatic circulation. The particles are then 
cleared via phagocytosis by alveolar macrophages. However depending on their 
particle size, chemical composition and bioavailability, the phagocytosis may 
become ineffective leading to accumulation of the CNTs which may then interact 
with cellular components, disrupt or alter cell functions (Powers et al., 2007). 
 
2.5.1 Associated impurities 
Metal impurities associated with CNTs such as iron, copper, chromium, vanadium 
and cobalt which are residual from the synthesis and purification are capable of 
redox cycling in which a single electron may be accepted or donated by the metal 
(Li et al., 1996; Ghio et al., 1999; Kagan et al., 2006). This action catalyzes 
reactions that produce reactive oxygen species (ROS) which induce oxidative 
stress. Oxidative stress can cause damage to biological components through 
oxidation of proteins, lipids and DNA. Oxidative stress is also identified as a 
dominant mechanism in the production of inflammation which can then impact a 
number of pathological processes such as airways disease, cardiovascular diseases 
or cancer (Mauderly et al., 1994). 
 
Shevdova et al., (2003) reported the first cytotoxicity study on CNTs. These 
researchers investigated the effects of unrefined SWCNTs on immortalized 
human epidermal keratinocytes (HaCaT). HaCaT cells were incubated for up to 
18 hours in media containing unrefined SWCNTs (0.06–0.24mg/mL). Exposure 
to SWCNTs resulted in increased free radical and peroxide generation and 
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depletion of total antioxidant reserves, loss in cell viability and morphological 
alterations to cellular structure. It was concluded that these effects were a result of 
high levels (approximately 30%) of iron catalyst present in the unrefined 
SWCNTs. 
 
One work concluded that the free-radical generation by commercial single-walled 
CNTs (SWCNTs) can be abolished by separating SWCNTs from iron impurities 
(Pulskamp et al., 2007). Lung cells were incubated with commercial single-walled 
and multi-walled CNTs, carbon black and quartz as reference particles as well as 
acid-treated single-walled CNTs (with reduced metal catalyst content). They 
found out that intracellular reactive oxygen species increased in a dose- and time-
dependent with the unpurified commercial CNTs whereas incubation with the acid 
treated CNTs had no effect.  
 
2.5.2 Particle size 
Size plays a role in how the body responds to, distributes and eliminates materials 
(Powers et al., 2007). Long tubes can be defined as tubes that significantly exceed 
the size of macrophages and are usually taken to be 10-20µm long (Sato et al., 
2005). Such tubes present problems for the macrophages which will have 
difficulties effectively phagocytozing and clearing them from cells and tissues. 
The clearance will be slower resulting in accumulation in the body so building up 
dose available to make contact with the cells. 
 
Kim et al., (2010) observed that high-aspect-ratio (10-15nm diameter and 
containing two different length distributions of 545 ± 230 and 10451 ± 8422nm 
length) MWCNTs were found to produce higher incidence of cytotoxicity than 
low-aspect-ratio MWCNTs (10-15nm diameter and length of 192 nm) in normal 
human embryonic lung cells. In the presence of less than 10% trace element 
content such as iron in MWCNT, the trace element exerted no marked effect on 
cellular viability indicating that the MWCNTs aspect ratio rather than impurities 
play a predominant role in the observed cytotoxicity attributed to MWCNTs. 
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Poland et al., (2008) studied the effect of length on CNT toxicity by injecting 
MWCNT and observing carcinogenic mechanisms in the abdominal cavity and on 
the diaphragm. The longer length (≥ 20μm) CNT resulted in an inflammatory 
response within 24 hours with consequent granuloma 7 days after injection. In the 
same study, shorter lengths of injected MWCNT were effectively taken up by 
macrophages with efficient phagocytosis. Hirano et al., (2008) further suggested 
that MWCNTs are recognized and interact with macrophage receptors on the 
plasma membrane and can rupture the membrane causing cytotoxicity and 
damage to the macrophage. 
 
Tian et al., (2006) assessed the toxicology of five carbon nanomaterials on human 
fibroblast cells in vitro including CNTs. They correlated the physico-chemical 
characteristics (excluding catalytic transition metals) of these nanomaterials to 
their toxic effect. They covered a wide range of variables, such as: physical 
dimensions, surface areas, dosages, aspect ratios and surface chemistry. They 
found that surface area is the variable that best predicts the potential toxicity of 
the refined carbon nanomaterials, and SWCNTs induced the strongest cellular 
apoptosis/necrosis. 
 
2.5.3 Solubility 
The other main cause of toxicity is the insolubility of the material. Part of the 
problem may be related to hydrophobicity of CNTs and their propensity to 
aggregate and interact with the cell membranes. There are indications that these 
problems may be mitigated by surface modifications of CNTs. Some 
modifications that decrease surface hydrophobicity and increase solubility of the 
CNTs have been shown to decrease CNTs cytotoxicity (Sayes t al., 2006). Hence, 
purification and chemical modification of CNTs aimed to increase solubility and 
decrease toxicity will be needed for their successful application in medicine. 
 
Water-soluble CNTs have been modified via chemical functionalization, allowing 
their binding to selective therapeutics or biologically relevant molecules, acting as 
specific signals presented via a CNT-based drug-delivery system (Pantarotto et 
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al., 2003; Pantarotto et al., 2004; Liu et al., 2005; Wu et al., 2005; Zhuang et al., 
2008). Pantarotto et al., (2003) functionalized CNTs with antigenic peptides. 
These functionalized carbon nanotubes were able to generate specific antibody 
responses, while the CNT support was non-immunogenic.  
 
Wu et al., (2005) assessed the characteristics of toxicity and uptake of water 
soluble CNTs functionalized with Amphotericin B (AmB) and fluorescein 
towards mammalian cells. The conjugation of AmB to CNTs clearly reduced the 
toxic effects of the antibiotic on mammalian cells. At the highest doses, more than 
40% of the cells died in the presence of AmB, whereas all the cells remained alive 
upon treatment with CNTs conjugated with AmB.  
 
Dumortier et al., (2006) addressed the question of impact of functionalized CNTs 
(f-CNTs) on cells of the immune system. They investigated the impact of two 
types of functionalized CNTs: 1,3-dipolar cycloaddition reaction and the 
oxidation/amidation treatment, respectively with relation to solubility. The 1,3 
cycloaddition f-CNTs were completely water soluble whilst the amidation f-CNTs 
formed stable suspension. They found that both types of functionalized CNTs are 
uptaken by B and T lymphocytes as well as macrophages in vitro, without 
affecting cell viability. 
 
The effects of the physicochemical modifications of CNTs due to the 
oxidation/amidation functionalization and the incorporation of the drug on their 
toxicity in neuronal cells will be investigated in this work. The physiochemical 
properties that will be assessed are length, surface area, residual metal impurities 
and degree of functionalization. Based on spectroscopic evidence this study 
provides information about the correlation of physicochemical properties variation 
with cytotoxicity, which may help bring a better understanding of carbon 
nanotube toxicity and may contribute to the reduction in data inconsistencies. 
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2.6 Purification of carbon nanotubes 
It is well known that the methods of production of CNTs generate impurities. The 
main impurities are by product carbonaceous species and residues from the 
transition metal catalysts used in preparing CNTs. Moreover, tubes are insoluble 
in many solvents due to Van der Waal and π-π interactions. These properties have 
been shown to be responsible for the toxicity of as prepared CNTs (Shvedova et 
al., 2003). Therefore, CNTs have to be purified to obtain the optimal performance 
of CNTs in various applications and to reduce cytotoxic side effects in the 
process. A number of purification methods have been developed to date. They can 
be categorized as: 1) filtration and chromatography techniques, (Duesberg et al., 
1999; Bandow et al.,1997; Park et al., 2006) 2) microwave heating methods, 
(Chajara et al., 2010; Harutyunyan et al., 2002) and 3) oxidative methods 
including liquid and gas phase oxidations (Li et al., 2004). 
 
2.6.1 Filtration and chromatography techniques 
Microfiltration is based on size or particle separation. It is a physical-based 
purification technique, and this purification neither results in huge sample loss nor 
in damaged CNTs. The other impurities and nanoparticles pass through the filter. 
The disadvantage of this technique is that it requires a number of successive 
filtration steps to achieve satisfactory purity, and this method does not readily 
yield size-selected tubes. Bandow et al., (1997) purified as-prepared SWCNTs by 
first soaking them in CS2 solution in order to extract amorphous carbon and 
fullerenes. Insoluble CS2 phases were trapped in a filter, and sonicated in an 
aqueous solution of 0.1% cationic surfactant (benzalkonium chloride) in order to 
separate the carbon nanospheres and metal nanoparticles from the SWCNTs. 
Through microfiltration with an overpressure of N2 gas, most of the nanospheres, 
C60, and C70 as well as metal nanoparticles were removed. 
 
Chromatography techniques are mainly used to separate small quantities of CNTs 
into fractions with small length and diameter distribution, in a non-destructive 
purification method. Notably, gel permeation chromatography and high 
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performance liquid chromatography coupled with size exclusion chromatography 
have been employed for this purpose (Duesberg et al., 1999; Farkas et al., 2002). 
 
2.6.2 Purification based on microwave heating 
In microwave treatment, microwaves couple to the residual metal catalyst and 
raise the local temperature, leading to both oxidation and rupturing of the carbon 
layer surrounding the catalyst particles. This method should be more effective at 
purifying arc-discharge CNTs as opposed to laser ablation CNTs because of the 
higher metal content in arc-discharge CNTs. In addition, as compared with 
traditional acid refluxing techniques, the processing time for this purification is 
relatively short, and does not damage the CNTs as much, compared with 
traditional acid refluxing techniques (Harutyunyan et al., 2002). 
 
2.6. 3 Purification by oxidative methods 
Purified CNTs can be achieved as a by-product of chemical functionalization. 
This method is focused on solubilizing CNTs by introducing other functional 
groups onto tube surfaces rather than removing impurities. Oxidative treatments 
have been the most popular method of purifying as they are able to remove both 
metal catalysts and amorphous carbons in large quantities of carbon nanotubes (Li 
et al., 2004). These treatments include liquid phase oxidation treatment, such as 
acid treatment (HNO3, HCl, H2SO4, etc.) and/or refluxing in water or H2O2, as 
well as gaseous phase oxidation heating in air or an oxygen atmosphere. The 
oxidative treatments always introduce oxygen-containing functional groups, such 
as phenols as well as carboxylic anhydrides and acids, at the tube ends and side 
walls defects sites.  
 
Particularly, the oxidatively introduced carboxylic functions are useful anchoring 
for further functionalization moieties, either through ionic or covalent linkages. 
Subsequently, these treatments involve opening of the tube ends (Liu et al., 1998) 
and shortening of tube length into the 100-300nm range, increasing the 
dispersibility in solvents (Chen et al., 1998; Hirsch, 2002; Tasis et al., 2003). Use 
of nitric acid (HNO3) is common as it is straight forward, inexpensive, and 
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reasonably effective in removing metal catalysts and amorphous carbon from 
large quantities of raw material (Li et al., 2004). Furthermore, it introduces defects 
which results in sp
3
 hybridization (Zhang et al., 2003). The dominant defects are 
carboxylic groups, which can lead to changes of electronic properties 
(Meyyappan, 2005). Gas phase oxidation (i.e., heating in air, oxygen, or other 
gases) is based on the principle of a selective oxidative etching process, wherein 
the carbonaceous species are oxidized at a faster rate than the actual CNTs 
themselves (Tsang et al., 1993). 
 
Of the purification methods currently employed, the HNO3:H2SO4 (3:1) 
concentrated acid mixture treatment with sonication was used in this study, this is 
because it is most successful in imparting carboxylic acid functionality to the cut 
tubes and producing a highly purified product (Li et al., 2004). In order to 
investigate the effects of different chemical oxidation conditions on degree of 
carboxylic acid loading, length and purity of MWCNTs, three temperature 
settings were employed. Based on spectroscopic evidence, this study provides 
information about purification, structural modification and intercalation aspects of 
these different oxidation conditions, which may help in choosing optimal methods 
for further device applications. 
 
2.7 Functionalization of Carbon nanotubes 
CNTs can undergo chemical functionalization to produce novel materials and to 
enhance solubility in various solvents for further applications. The main 
approaches for the functionalization of CNTs can be grouped into three 
categories: (a) purification-oxidation; (b) the covalent attachment of chemical 
groups through reactions on the conjugated skeleton of CNT; (c) the non-covalent 
adsorption or wrapping of various functional molecules onto the tube walls. 
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2.7.1 Non-covalent functionalization of carbon nanotubes 
Non-covalent methods of functionalizing CNTs have been largely done to 
increase their dispersion in most solvents and purify CNTs from amorphous 
carbon and metal impurities whilst preserving their aromatic structure and 
electronic properties unlike oxidative acid treatment (Meyyappan, 2005). 
Wrapping of the CNTs is a general phenomenon, driven largely by a 
thermodynamic drive to eliminate the hydrophobic interface between the carbon 
nanotubes and their aqueous medium. The CNT-adsorbate conjugation is caused 
by π–π stacking interactions between the aromatic part of the adsorbate and the 
graphitic sidewall of CNTs. Methods include Polymer (Chen et al., 2002; Liu et 
al., 2005; Kang et al., 2009), protein and DNA wrapping (Zheng et al., 2003) and 
surfactant adsorption (Islam et al., 2003; Jiang et al., 2003; Chen et al., 2001). The 
dispersion methods involve ultra-sonication, centrifugation and /or filtration. 
 
a) Surfactants 
A series of anionic, cationic and non-ionic surfactants have already been proposed 
to disperse CNTs. Sodium dodecyl sulphate (SDS) and Triton X-100 were used to 
obtain CNT suspensions up to 0.1 and 0.5mg/mL, respectively (Islam et al., 
2003). Chen et al., (2001) studied the non-covalent functionalization of CNTs via 
π- π interactions with 1-pyrenebutanoic acid activated succinimidyl ester. It 
immobilizes the proteins by promptly reacting with the amino groups present in 
the proteins like ferritin or streptavidin. The solubility of CNTs was between 0.1 
and 0.7mg/mL, which is rather low but acceptable for biological use. 
 
 
Figure 2.6 How surfactants adsorb on the tube surface (Islam et al., 2003). 
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b) Polymers 
The mechanism of dispersion is based on polymers wrapping around the CNTs 
creating hydrophobic interactions which break the water–water interactions 
preventing the squeezing out of the insoluble CNTs. The CNTs are covered by the 
hydrophobic backbone of the polymer whilst the hydrophilic groups are exposed 
to the surface to display water solubility. O’Connell et al., (2001) reported that 
SWCNTs had been reversibly solubilized in water in the g/l concentration range 
by non-covalently associating them with a variety of linear polymers such as 
polyvinyl pyrrolidone (PVP) and polystyrene sulfonate (PSS). They demonstrated 
that the association between the polymer and the SWCNT is robust, not dependent 
upon the presence of excess polymer in solution, and is uniform along the sides of 
the carbon nanotubes. 
 
Liu et al., (2007) found that water-soluble SWCNTs with poly(ethylene glycol) 
(PEG) functionalization allowed for surprisingly high degrees of π-π stacking of 
aromatic molecules, with a cancer drug (doxorubicin) and a widely used 
fluorescent molecule. The strength of π-π stacking of aromatic molecules was 
dependent on the carbon nanotube diameter, leading to a method for controlling 
the release rate of molecules from CNTs by using carbon nanotubes with a 
suitable diameter. 
 
c) Proteins and DNA 
Self-assembly processes similar to π–π stacking interactions typical of double 
strand DNA can be exploited to disperse carbon nanotubes. Zheng et al., (2003) 
sonicated the CNTs in the presence of single strand DNA to form a CNT-DNA 
conjugate which was highly stable and soluble in the mg/ml range. A molecular 
modelling study was used to explain the formation of the hybrids exerted by DNA 
wrapping and subsequent CNT debundling. Amphiphilic and cyclic peptide 
sequences play a large role as water solubility enhancers. The peptides can be 
selected from phase display libraries or by design. 
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Figure 2.7 Some possible wrapping arrangements (O'Connell et al., 2001) 
 
2.7.2 “Defect” Functionalization at the Tips and Sidewalls 
 
Besides non-covalent procedures, CNTs can also be cut and functionalized 
simultaneously, becoming soluble in polar organic solvents, acids and water 
without the aid of sonication, surfactants, or any other means, by simply treating 
them with oxidizing agents such as strong acids (Li et al., 2004). This oxidizing 
procedure is usually known as “defect functionalization”, since it takes place at 
the ends or in correspondence of pre-existing defects of CNTs. After that, the 
carboxylic acid groups and the carboxylated fractions introduced by oxidization 
treatment, can further be derivative functionalize amidation, esterification or 
through the zwitterionic COO−NH3
+
 formation (Scheme 2.3), (Tasis et al., 2003). 
This often requires activation of the carboxylic acids by thionyl chloride, N-
hydroxysuccinimide (NHS), or carbodiimide (e.g. Diisopropyl carbodiimide) in 
order to get highly reactive intermediates.  
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Scheme 2.3 End wall functionalization with amines: A: Covalent chemistry at the 
open ends of SWCNTs; B: Ionic functionalization of SWCNTs (Tasis et al., 2003) 
 
Voussoughi et al. (2009) successfully conjugated a drug by amidation. Initially 
they directly coupled ethylene-diamine with the carboxylic groups to introduce 
amino groups via amide formation. Finally, these functionalized carbon nanotubes 
were conjugated to Amphotericin B, the most effective antibiotic though, toxic in 
the treatment of chronic fungal infections, via a two-step process of diimide-
activated amidation. DNA was also bound to CNTs via amide linkage (Liu et al., 
2005; Kam et al., 2006) and reversibly hybridized with its complementary 
sequence, offering the possibility to reutilize the derived single-strand DNA-
CNTs in a second-round of hybridization. 
 
2.7.3 Covalent Functionalization on the External Sidewalls  
Among the most powerful methodologies aimed to functionalize CNTs, a special 
kind of 1,3-dipolar cycloaddition represents a fascinating example of covalent 
bonding: it is extremely versatile, since it requires only an α-amino acid (or 
A 
B 
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correspondent ester) reacting with an aldehyde or keton, to generate in situ 
azomethine ylides that are very reactive and thus determine the formation of 
pyrrolidine rings on the sidewall of CNTs (Tagmatarchis et al., 2004), (Scheme 
2.4).  
 
 
 
 
 
 
 
 
 
Scheme 2.4 1, 3 cycloaddition reaction to CNTs (Singh et al., 2009) 
 
Wu et al., (2005) functionalized MWCNTs with Amphotericin B (AmB), which is 
a potentantimycotic drug normally used for the treatment of chronic fungal 
infections. However, the drug also displays a remarkable toxicity towards 
mammalian cells, presumably because of its low water solubility and its tendency 
to form aggregates. Multi-walled CNTs were treated under strong acidic 
conditions for 8 hours to reduce their length to about 180–940nm. The carboxylic 
groups were coupled with a phthalimide mono-protected triethylene glycol-
diamine. Subsequently, the tubes underwent the 1,3-dipolar cycloaddition reaction 
to introduce N-functionalized pyrrolidine rings, bearing Boc-protected amino 
groups, on the external walls of the tubes. Being the two protecting groups 
reciprocally orthogonal, they allowed the incorporation of a fluorescent dye to 
follow the cell internalization of the conjugate, while the drug molecule AmB 
could exert its antifungal action. 
 
2.7.4 Encapsulation inside CNTs 
Although many biomolecules, adsorbed or bound onto the surface of nanodevices 
have been mentioned to display an improved therapeutic activity, i.e. increased 
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water dispersibility, a better bioavailability and a reduced toxicological profile, 
there are many other examples showing that the interaction with the carrier or the 
surrounding environment could determine inactivation or even degradation of 
these molecules. For this reason, the recent use of CNTs to encapsulate molecules 
has rendered these nanosystems particularly suitable for additional applications 
such as material storage (Yanagi et al., 2006) and drug delivery (Ren et al., 2008). 
The advantage of this methodology lies on the ability of carbon nanotubes to 
provide protection and to control the release of loaded molecules, thus prolonging 
the effect of eventual drugs.  
 
Nano-extraction: For this process to happen, the mutual interactions among 
graphene sheets, molecules and solvent must be accurately balanced, in the sense 
that both CNTs and guest molecules must have poor affinity to the solvent, but 
strong reciprocal attraction. If these conditions are ensured, the desired molecules 
can be deposited within the CNTs as the most stable site (Yudasaka et al., 2003). 
 
Nano-condensation: It is difficult to understand the mechanism of nano-
condensation. Competing processes are the adsorption of solvent molecules onto 
the tube wall, evaporation of solvent molecules, segregation or self-crystallization 
of guest molecules, and deposition of guest molecules inside the tube walls. The 
following mechanism is suggested: the guest molecules-solvent remain adsorbed 
to the CNT surface via the Van der Waals force. The guest molecules then 
migrate through the thin solvent-layers, and eventually depositing themselves at 
the most stable sites inside the carbon nanotubes (Berber et al., 2002). There 
should be strong affinities between the guest-molecule, solvent and CNTs 
otherwise the solvent-guest molecule solution will be unable to overcome the 
absorption force due to the filtration paper. 
 
Ren et al., (2008) investigated the possibility to incorporate a bioactive molecule 
inside carbon nanotubes with the purpose to provide protection, storage and 
controlled release. They adopted one of the procedures introduced by Yudasaka’s 
group to encapsulate fullerene particles defined as “nano-extraction” (Yudasaka et 
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al., 2003). They performed a two-step nano-extraction to initially load an 
anticancer drug, hexamethylmelamine, inside SWCNTs and subsequently to seal 
the tubes with fullerenes (C60). The success of encapsulation was confirmed by 
TEM images and by Raman analysis. They further demonstrated that it was 
possible to open these nano-bottles and to extract the entrapped drug. 
 
Another interesting encapsulation of a drug inside CNTs has been obtained by 
Hampel’s group, who also investigated the influence of CNTs filled with a 
carboplatin on tumour cell growth (Hampel et al., 2008). CNTs were opened by 
both thermal treatment and strong acidic conditions, while the drug was 
incorporated through a wet chemical approach, in which capillarity acted as the 
driving force. They found that the structure of carboplatin incorporated into the 
CNTs was retained and in vitro studies showed that carboplatin-filled CNTs 
inhibited growth of bladder cancer cells whilst the unfilled, opened CNTs barely 
affected cancer cell growth. 
 
The covalent functionalization of carbon nanotubes is more robust and better 
controllable compared to procedures based on non-covalent methods, and it offers 
the possibility of introducing both the drug riluzole and fluorescent probe. 
Consequently, in this study the covalent functionalisation was used in all 
conjugation processes. 
 
2.8 Biomedical applications of carbon nanotubes 
New materials for the intracellular transport of biological cargos such as DNA, 
proteins, and drug molecules have been actively sought to effectively breach the 
cell-membrane barriers for delivery and enabling functionality of extracellular 
agents. Carbon nanotubes (CNTs) have been recently shown to shuttle various 
molecular cargos inside living cells including proteins (Pantarotto et al., 2004; 
Kam et al., 2004; Kam et al., 2005), drugs (Wu et al., 2005; Bianco et al., 2005) 
and nucleic acids (Pantarotto et al., 2004). 
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There is still much of discrepancy regarding the uptake mechanism; (Kam et al., 
2004; Kam et al., 2005; Liu et al., 2005) have suggested that CNTs traverse the 
cellular membrane through endocytosis, whereas (Pantarotto et al., 2004; Wu et 
al., 2005; Cai et al., 2005) have suggested an energy independent non-endocytotic 
mechanism that involves insertion and diffusion of nanotubes through the lipid 
bilayer of the cell membrane.  
 
The ability to translocate into cells of functionalized CNTs has generated interest 
in using CNTs as drug or vaccine delivery vehicles and to this end there have 
been several studies conducted on CNT functionalization with vaccine, drug 
molecules and DNA (Pantarotto et al., 2003; Pantarotto et al., 2003; Pantarotto et 
al., 2004; Wu et al., 2005; Gao et al., 2006; Liu et al., 2009). 
 
Pantorroto et al., (2003) used functionalized SWCNT to create a vaccine delivery 
device by attaching a small peptide sequence from the foot and mouth disease 
virus (FMDV) to the side-wall of purified SWCNT via 1,3-dipolar cycloaddition. 
Their study demonstrated that the conformation of the peptide sequence was 
maintained and recognized by mono- and poly-clonal antibodies, and that the 
SWCNT-FMDV peptide complex induced a specific anti-body response in vivo. 
The authors also concluded that there was no cross reactivity (immune response) 
to the SWCNT in vivo, suggesting that vaccine delivery is a viable application for 
CNTs. 
 
Wu et al., (2005) attached an antifungal drug Amphotericin B (AmB) to CNTs 
using the 1, 3 cycloaddition reactions. They revealed that AmB covalently linked 
to CNTs is taken up by mammalian cells without presenting any specific toxic 
effect. Furthermore, AmB bound to CNTs preserved its high antifungal activity 
showing that CNTs can be effective and efficient nano-carriers for drug delivery 
across cell membranes. 
 
Liu et al., (2009) attached a cancer chemotherapy drug doxorubicin (DOX) 
molecule on to prefunctionalized carbon nanotubes, for in vivo cancer therapy. 
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They demonstrated that DOX-loaded prefunctionalized carbon nanotubes induced 
significant U87 cancer cell death and cell apoptosis, similar to free DOX. 
However, the main advantage of using functionalized CNTs as a drug carrier 
compared to free drug is their potential to target delivery for selective destruction 
of certain types of cells, reducing the toxicity to non-targeted cells. 
Carbon nanotubes have also been investigated as biocompatible non viral 
transporters which can also achieve targeted delivery when functionalized with 
nucleic acids (Pantarotto et al., 2004). Pantarotto et al., 2005 reported carbon 
nanotube delivery of the gene into cells, with no apparent toxic effects. Gao et al., 
(2006) found that amino- functionalized multiwalled carbon nanotubes are able to 
interact with plasmid DNA and deliver the green fluorescence protein (GFP) gene 
into cultured human cells. CNTs functionalized with genes showed gene 
expression levels which were up to 10 times higher than those achieved with 
DNA alone. This means that functionalized CNTs can be used to overcome one of 
the challenges for non-viral gene delivery, which is to achieve high gene transfer 
efficiency.  
2.9 Characterization of Carbon nanotubes and their functionalized 
derivatives 
Bulk samples of CNTs contain nanotubes of different diameter, chirality, surface 
area, length, and also metal catalysts and carbon impurities. The characteristics of 
the CNTs and the impurities depend on the procedures followed for the synthesis, 
purification, and modification of CNTs. A large number of analytical techniques 
are currently available for the characterization of nanostructured materials and 
carbon materials. Powerful tools such as electron microscopy, Raman 
spectroscopy, Thermogravimetric analysis (TGA), and optical absorption 
spectroscopy are utilized in most of the published work on CNTs. 
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A complete characterization of a carbon nanotube sample should include the 
following information: 
1) The quantitative estimate of metal content. 
2) The type and the amount of carbonaceous impurities. 
3) Diameter distribution and length of the carbon nanotubes. 
4) Crystalline quality, degree of bundling, and presence of defects in the carbon 
nanotube walls and tips. 
5) Degree of functionalization of the carbon nanotubes and type of the functional 
chemical groups. 
 
2.9.1 Transmission Electron Microscope  
CNTs bundles and individual CNTs can be observed by Transmission Electron 
Microscope (TEM). Sample impurities can be detected and identified by TEM 
(Bandow et al., 1998; Park et al., 2006). Metal nanoparticles are easily recognized 
like dark spots in TEM images, usually covered by graphitic structures. Graphitic 
particles appear like coiled or layered globules, and amorphous carbon constitutes 
disordered aggregates surrounding the CNTs. Furthermore information on the 
diameter and length distribution can be obtained from the TEM analysis. 
 
2.9.2 Fourier transform infrared 
Fourier transform infrared (FTIR) absorption spectroscopy is a useful technique 
for the detection of surface functional groups in solids. FTIR spectroscopy has 
been successfully applied to follow chemical reactions in nanomaterial samples 
(Baudot et al., 2010). 
 
2.9.3 Raman Spectroscopy 
The Raman bands of experimental CNTs spectra provide information about the 
diameter, chirality, conductor or semiconductor character, crystallinity, and 
functionalization degree of CNTs (Jorio et al., 2001; Delhaes et al., 2006; Liu et 
al., 2008). The most prominent features in the Raman spectrum of MWCNTs are: 
a) the tangential modes or G band, around 1600cm
-1
. The tangential modes 
originate from the vibrations of the carbon atoms in CNTs walls in the direction of 
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the tube axis. b) The radial breathing modes (RBM), around 150cm
-1
, with all the 
carbon atoms vibrating in phase and in the nanotube radial direction. c) The D 
band around 1300cm
-1
, associated to disordered carbon forms or defects in 
MWCNTs. The G band intensity, or the G/D intensity ratio, is an appropriate 
index for the purity assessment of CNT samples and degree of functionalization. 
 
2.9.4 BET surface area analysis 
BET theory aims to explain the physical adsorption of gas molecules on a solid 
surface and serves as the basis for an important analysis technique for the 
measurement of the specific surface area of a material. Controlled doses of an 
inert gas, such as nitrogen or argon, are introduced and the gas is adsorbed, or 
alternatively, withdrawn and desorbed. The sample material is placed in a vacuum 
chamber at a constant and very low temperature, usually at the temperature of 
liquid nitrogen (-195.6°C), and subjected to a wide range of pressures, to generate 
adsorption and desorption isotherms. Knowing the area occupied by one adsorbate 
molecule, σ (for example, σ = 16.2Å2 for nitrogen), and using an adsorption 
model, the total surface area of the material can be determined. 
Table 2.2 Analytical techniques for CNTs 
Analytical Techniques  Structural Information 
Thermal Analysis 
 
Microscopy 
Spectroscopy 
 
 
 
 
 
TGA 
DTA 
TEM 
FTIR 
Raman 
 
UV-vis-
NIR 
BET 
Purity and thermal stability 
Degree of functionalization 
Diameter, length, chirality and purity 
Nature of functional groups, 
Amount of carbon impurities and 
damage/disorder, degree of 
functionalization, diameter and 
chirality 
helicity and degree of 
functionalization, 
surface area and pore volume 
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2.10 Cytotoxicity Assays 
2.10.1 CytoTox-Glo™ Cytotoxicity Assay 
The CytoTox-Glo™ Cytotoxicity Assay is a single-reagent-addition, 
homogeneous, luminescent assay that allows measurement of the number of dead 
cells in cell populations. The CytoTox-Glo™ Assay measures a distinct protease 
activity associated with cytotoxicity (Niles et al., 2007). The assay uses a 
luminogenic peptide substrate (alanyl-alanylphenylalanyl-aminoluciferin; AAF-
Glo™ substrate) to measure “dead-cell protease activity”, which has been released 
from cells that have lost membrane integrity (Scheme 2.5). The AAF-Glo™ 
substrate cannot cross the intact membrane of live cells and does not generate any 
appreciable signal from the live-cell population. The assay selectively detects 
dead cells. The “dead-cell” protease cleaves the Ala-Ala-Phe peptide from the 
AAF-Glo™ Substrate leaving aminoluciferin. Aminoluciferin becomes a substrate 
for the Ultra-Glo™ Luciferase generating light. 
 
 
Scheme 2.5 Morphology of cells when viable and when dead 
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2.10.2 LDH release 
Lactate dehydrogenase (LDH) is a cytosolic enzyme present within all 
mammalian cells. The normal plasma membrane is impermeable to LDH, but 
damage to the cell membrane results in a change in the membrane permeability 
and subsequent leakage of LDH into the extra cellular fluid (Decker et al., 1988). 
In vitro release of LDH from cells provides an accurate measure of cell membrane 
integrity and cell viability. As a result, the release of lactate dehydrogenase has 
proved to be a popular and reliable test for cytotoxicity in both immunological 
studies, where it has superseded the radioactive chromium release test as an assay 
for cellular cytotoxicity (Brander et al., 1993). 
 
In order to assess the effects of a biomaterial on mammalian cell cultures, cells are 
exposed to varying concentrations of test material over a period of days. The 
release of LDH into culture supernatant correlates with the amount of cell death 
and membrane damage, providing an accurate measure of the cellular toxicity 
induced by the test substance. Promega's CytoTox 96® Non-Radioactive 
Cytotoxicity Assay is based upon a coupled enzymatic assay involving the 
conversion of a tetrazolium salt, 2-p-(iodophenyl)-3-(p-nitrophenyl)-5-
phenyltetrazolium chloride (INT), into a formazan product. The reaction is 
catalyzed by LDH released from cells and diaphorase present in the assay 
substrate mixture. 
 
 The chemical reactions are presented below: 
Lactate + NAD
+
 --> Pyruvate + NADH                                                2.3 
 
NADH + INT -->NAD
+
 + Formazan                                                    2.4 
 
In the CytoTox 96® Non-Radioactive Cytotoxicity Assay, formazan 
concentrations are determined by measuring optical absorbance at 492nm in a 96 
well format. 
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The CytoTox 96® Non-Radioactive Cytotoxicity Assay was used to measure 
death of a single cell type in culture, such as after treatment with a cytotoxic drug 
(Singer et al., 1999) and to measure cell death initiated by transfected N-methyl-
D-aspartate (NMDA) receptors (Miroslav et al., 1995). Incubated HEK 293 cells 
were transfected with the required NMDA receptor subunit genes using calcium 
phosphate transfection. After 20 hours, cells were centrifuged and the supernatant 
medium samples to assess LDH released due to cell death (experimental LDH). 
Maximum LDH activity was assessed by freeze-thaw lysing the transfected cells, 
collecting volumes of the resulting medium and processing as above. The 
percentage cell death was calculated by dividing the experimental LDH assay by 
the maximum LDH assay. 
 
Cell viability tests and neuronal injuries were determined based on the 
colorimetric CytoTox 96® Non-Radioactive Cytotoxicity Assay, which 
quantitatively measures lactate dehydrogenase (LDH), a stable cytosolic enzyme 
that is released upon cell lysis. Visible wavelength absorbance data was collected 
using a Victor X3 multimode plate reader. Advantages of the CytoTox 96® Non-
Radioactive Cytotoxicity Assay are that it eliminates labeling of cells before 
experiment, allows use of a standard plate reader and can reveal early, low-level 
cytotoxicity. 
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3. METHODS 
3.1 General procedures 
The general procedures involved in this work are: (i) synthesizing the nanotubes, 
ii) functionalization of the carbon nanotubes with the drug and florescent probe, 
(iii) characterisation of the drug-CNT conjugate iv) determining the loading 
efficiency and rate law v) tracing the cellular uptake vi) evaluating the correlation 
between the physiochemical properties of the drug-loaded CNTs with toxicity vii) 
determining the neuroprotectiveness of the riluzole-CNT conjugate in vitro. 
 
3.2 Reagents, reactants and solvents 
All the reagents were obtained from commercial sources and used without further 
purification. Riluzole, Fluorescein isothiocyanate, N-Boc-2, 2’ (ethylenedioxy) 
diethyl amine, Ferrocene, Glutamic acid and Diisopropylcarbodiimide were 
purchased from Sigma (St. Louis, USA). Dimethylformamide, sulphuric acid, 
nitric acid, methanol, Sodium hydroxide and paraformaldehyde were purchased 
from Merck chemicals, (Johannesburg, South Africa). The Neural cell line was 
purchased from Health Science Research Resources Bank (Japan). The RPMI-
1640 medium, fetal bovine serum and horse serum were purchased from Sigma 
(St. Louis, USA). Penicillin/streptomycin was purchased from Highveld Biology 
(Johannesburg, South Africa). Acetylene and Argon were purchased from Afrox 
(Johannesburg, South Africa). The CytoTox Glo
TM
 cytotoxicity assay and 
Cytotox-96 non-radioactive cytotoxicity assay was purchased from Promega 
(Madison, USA). 
 
3.3 Synthesis of carbon nanotubes 
The CNTs were synthesized using the vertical Catalytic Chemical Vapor 
Deposition (CCVD) (Figure 3.1) according to the procedure described in Iyuke et 
al., (2007) with minor alterations. Acetylene was used as the carbon source and 
ferrocene (10mg) as the catalyst. Ferrocene was supported on a solid to increase 
the surface area for higher yield of the catalytic reaction.  
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The reactor was operated at high temperatures of about 900ºC for a reaction time 
of 20 minutes. Argon gas was used to purge the system of oxygen from ambient 
temperatures to 100ºC.  
 
Figure 3.1 Vertical CCVD reactor set up used for the synthesis of MWCNTs  
 
3.4 Purification 
The as synthesized MWCNTs were oxidized in strong acid mixture to allow for 
the removal of metallic impurities (catalysts and fullerene particles) and opening 
of tips. This process also led to the generation of carboxylic groups (COOH) on 
the CNT walls (Li et al., 2004, Scheme 3.1). In a typical experiment, a 100mg of 
as-prepared MWCNTs were added to 400 ml of a mixture of sulfuric acid and 
nitric acid in a composition of 3/1 by volume. The mixture was sonicated in a 
water bath for 10 minutes at room temperature and was then heated at 100
o
C for 1 
hour to conduct the acid treatment (Scheme 3.1). Other conditions of acid 
treatments include 60
o
C for 6 hours and 40
o
C for 24 hours. At the end of acid 
treatment, each mixture was diluted with distilled water, followed by centrifuging 
at 7000rpm. The product (ox-MWCNTs) was washed with distilled water till the 
supernatant had a neutral pH and dried at room temperature for one day. The 
structure of the ox-MWCNTs was examined by TEM (Jeol JS-100 at 80kV). The 
thermal stability of the ox-MWCNTs was examined by thermal gravimetric 
analysis (TGA, TA Instruments, TGA 2050). The formation of the COOH groups 
on CNTs was verified by Fourier transform infrared spectrophotometer (FTIR, 
Perkin Elmer, Spectrum One) and the concentrations of the COOH groups were 
quantitatively evaluated by titrations. 
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Scheme 3.1 The purification of MWCNTs by acid oxidation with sulphuric acid 
and nitric acid mixture (Singh et al., 2009). 
 
3.4.1 Quantitative Assessment of the carboxylic functional group loading 
Acid-base titration of ox-MWCNTs is normally used for the quantification of 
surface functional groups (Chen et al., 2001). It is assumed that the surface 
functional groups of the CNTs are weak acidic groups more specifically 
carboxylic acid group (COOH). Ox-MWCNTs (50mg) were added into a 25-ml 
0.04N sodium hydroxide (NaOH) solution in a 100ml flask. The flask was sealed 
and placed in a shaking incubator at 25°C at 150rpm for 48 hours. The dispersion 
was then filtered. The filtrate was titrated with a 0.04N standardised HCl solution 
to a pH of 7 to determine the excess NaOH in the solution and the concentration 
of the carboxylic group ([COOH]) on the ox-MWCNTs. 
 
3.5 Conjugation of riluzole to the acid oxidized MWCNTs 
Amidation reactions can be carried out on oxidized MWCNTs by standard 
methods either using acid chlorides as intermediates or carbodiimide-activated 
coupling (Dumortier al., 2006). Riluzole was conjugated to the ox-MWCNTs 
using the carbodiimide-activated amidation (Scheme 3.1). The carbodiimide 
activates the carboxylic acid moieties.  
 
H2SO4, HNO3, 
Sonication 
 
Oxidation 
H2SO4:HNO3, 3:1 
with sonication 
As-prepared MWCNT 
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Scheme 3.2 The carbodiimide activated amidation of ox-MWCNTs with riluzole 
(Singh et al., 2009) 
 
In a typical experiment ox-MWCNTs (100mg, mmols depends on the temperature 
of oxidation, Table 3.1) were dispersed into 20ml Dimethylformamide (DMF) in a 
100ml flask. Riluzole (1.5 x [COOH], mg depend on the ox-MWCNTs sample 
used, Table 3.1) dispersed in 5ml DMF was then added to the CNTs and the 
mixture stirred at room temperature for 3 hours. During the reaction the coupling 
reagent Diisopropylcarbodiimide (DIC) (1 x [COOH], volume depends on the ox-
MWCNTs sample used, Table 3.1) in 5ml DMF was gradually added to activate 
the carboxyl group during the coupling reaction. After the 3 hours the reaction 
mixture was centrifuged at 7000rpm and the solid product was washed three times 
with methanol to remove excess drug. The solid product was dried at room 
temperature for 24 hours.  
 
RNH2, DIC Amidation 
Riluzole 
R =       
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Table 3.1 COOH loading as calculated from the acid-base titrations (Appendix 
A2) and amounts of riluzole and DIC used during the amidation process 
Sample [COOH] loading 
(mmols/100mg) 
Riluzole DIC 
(µl) 
Mass/mg Mmols 
Ox-MWCNT@40 
Ox-MWCNT@60 
Ox-MWCNT@100 
0.011 
0.0198 
0.0356 
3.86 
6.96 
12.51 
0.016 
0.030 
0.053 
1.72 
3.10 
5.57 
 
3.6 Fluorescent labelling of riluzole loaded MWCNTs 
3.6.1 Amidation of N-Boc-2,2’(Ethylenedioxy)diethylamine to ox-MWCNTs  
Ox-MWCNTs@100 (100mg, 0.0356mmol) dispersed in DMF (10ml) were 
equilibrated with DIC (1.67µl in 1ml of DMF, 0.0107mmols) for 30 minutes. N-
Boc-2,2’(Ethylenedioxy)diethylamine (DEA-Boc) (2.54µl, 0.0107mmols) was 
added to the mixture and the reaction mixture stirred at room temperature for 3 
hours.  
 
Scheme 3.3 The carbodiimide activated amidation of ox-MWCNTs with N-Boc-
2,2’(Ethylenedioxy)diethylamine (Singh et al., 2009) 
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The reaction mixture was washed 2 times by centrifuging at 7000rpm to remove 
the excess solvent (Scheme 3.1). The solid product (MWCNT-DEA-Boc) was 
then dried at room temperature for 24 hours. The product was characterised by 
FTIR and UV-vis spectroscopy. 
 
3.6.2 Deprotection of BOC from the MWCNT-DEA-Boc conjugate 
A solution mixture of HCl/dioxane (0.4ml/9.6ml) was stirred in an ice bath for 15 
minutes (Han et al., 2001). The MWCNT-DEA-Boc (100mg) was added and the 
ice bath removed. The reaction suspension was then stirred at room temperature 
for 1 hour. The reaction suspension was then centrifuged at 7000rpm to remove 
excess solvent and washed 3 times with dioxane before being dried at room 
temperature overnight. The removal of the protecting group was ascertained by 
HNMR. 
 
3.6.3 Conjugation of riluzole to MWCNT-DEA conjugates 
MWCNT-DEA (cleaved of Boc), (100mg, 0.025mmols) dispersed in DMF (4ml) 
were equilibrated with DIC (3.9µl, 0.025mmols) for 30 minutes. Riluzole (8.6mg, 
0.025mmol) dispersed in DMF (1ml) was added and the mixture mixed for 3 
hours at room temperature. The reaction mixture was washed 2 times by 
centrifuging at 7000rpm to remove the excess solvent. The solid product was then 
dried at room temperature for 24 hours while the product was characterized by 
FTIR and UV-vis spectroscopy.  
 
3.6.4 Conjugation of Flourescein Isothiocyanate (FITC) to the riluzole loaded 
MWCNT 
Amino-functionalised MWCNTs (riluzole-MWCNT-DEA) (20mg) were 
dispersed in 2ml of DMF. A solution of flourescein isothiocyanate (FITC) (2mg) 
in 1ml of DMF was added and the solution was stirred overnight at room 
temperature in the dark. The solvent was removed and the product was washed in 
methanol three times before being dried at room temperature. 
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3.7 Characterization of the drug loaded carbon nanotubes 
Characterization and analysis of drug-loaded CNTs conjugate was carried out by a 
number of different techniques. 
 
3.7.1 Transmission electron microscopy  
Transmission electron microscopy (TEM) was used to provide the visualization 
information on tube dimensions and level of aggregation. Samples were prepared 
for TEM by suspending ~0.02mg in 1ml of methanol. The solutions were 
sonicated for 10 minutes and 2 drops were placed on copper 400 mesh grids. TEM 
images were obtained on a Joel JEM 100S TEM operating at 80kV.  
 
3.7.2 Thermogravimetric analysis  
Information on the CNTs purity could be obtained from the TGA based on the 
extent of non-oxidizable residue at high temperature and on the difference 
between the burn temperature of amorphous carbon and that of the CNTs. The 
non oxidizable residue was taken to be residual metal catalysts. The 
thermogravimetric analysis was done in air at a rate of 5cm
3
/min from room 
temperature to 900ºC. The following were monitored, 1) the weight loss of the 
CNTs and 2) the thermal stability of the purified MWCNTs and drug loaded 
MWCNTs. 
 
3.7.3 UV-visible spectroscopy  
Perkin Elmer double beam spectrometer was used to estimate the amount of drug 
incorporated onto the acid ox-MWCNTs. Riluzole in Dimethylformamide (DMF) 
gives a maximum absorbance in the UV region at λmax=311nm. A calibration 
curve of riluzole in DMF at different concentration was prepared using the 
specific absorbance peak at 311nm. The calibration curve was linear with a 
correlation coefficient of R
2
=0.99 (Figure A1, Table A7).  This absorbance was 
correlated to the calibration curve and the amount of riluzole was determined. The 
UV-vis spectrometer was also used to verify the presence of the FITC and the 
drug. 
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3.7.4 Fourier transform infrared  
Fourier transform infrared (FTIR) spectrometer was used to study the structural 
changes in the riluzole-MWCNTs conjugate. Riluzole, ox-MWCNTs and the 
riluzole-MWCNTs conjugate were mixed with potassium bromide (KBr) and then 
compressed with a hydraulic press into 1mm thick pellet discs. Perkin-Elmer 
spectrometer (Spectrum one) that enables KBr disc analysis was used. Four scans 
were averaged with resolution of 4cm
-1
.The formation of amide functionalities in 
the MWCNT-riluzole conjugate, was verified by Fourier transform infrared 
spectrophotometer (FTIR, Perkin Elmer, Spectrum One) 
 
3.7.5 Raman Spectroscopy 
Raman spectroscopy was used to provide the structural characteristics of the 
carbon nanotubes and an indication of the degree of functionalization. The D band 
intensity represented the existence of defects and other disorder-induced effects 
for any type of carbon. The D band can represent sp
3
 bonds while the G band can 
be attributed to a C-C stretching mode of well graphitized CNTs i.e. sp
2
 bonds. 
The relative intensity ratio of the D and G bands is known to depend on the 
structural characteristics of CNTs and was used to measure the disorder in CNTs. 
The increase in the ratio of the D band intensity to the G band intensity (ID/IG) is 
the key evidence for sidewall functionalization, due to the increased sp
3
-content in 
the sp
2
 framework of the CNT sidewalls. In addition it shows an increase in the 
defect structure and a decrease in graphitization. A 514.5nm line of an argon ion 
laser was used as the excitation line, and the measurements were done using the 
micro-Raman attachment of a Jobin-Yvon T64000 Raman spectrometer operated 
in single spectrograph mode with a 600 lines/mm grating and a liquid nitrogen 
cooled CCD detector. 
 
3.7.6 BET Analyzer 
At least about 0.2g of samples were degassed in N2 at 150°C overnight prior to 
analysis using a Micromeritics Flow Prep 060, sample degas system. The surface 
areas and pore size distributions were then obtained at -196°C. The pore size 
distribution with specific surface areas of the samples, were determined via N2 
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adsorption/desorption according to the BET method using a Micromeritics Tristar, 
surface area and porosity analyzer. In order to confirm the accuracy of the results, 
the analysis was repeated at least twice for all samples and the measurements 
were in good agreement. 
 
3.8 Kinetics of conjugation 
Ox-MWCNTs@100 (~100mg, 0.00356mmols) were divided into 18mg/vial to make 
six vials representing the six times at which the reaction was to be stopped. 
Riluzole and DIC initially diluted in DMF were then added to each vial in equal 
aliquots and the mixture was stirred at room temperature for 30, 60, 90, 120, 150 
and 180 minutes, respectively. The concentration of DIC and ox-MWCNTs was 
kept constant whilst the concentration of riluzole was increased from 0.5x 
[COOH], 1x [COOH], 1.5x [COOH] to 1.7x [COOH] equivalents per run. At the 
predetermined times the reaction was stopped and the mixture filtered using a 
0.22µm PDVF membrane filter (Millipore Co., Bedford, MA, USA) and 
centrifuged at 10,000rpm. The supernatant was then removed and the presence of 
the riluzole in the solution estimated via UV spectroscopy (Perkin Elmer 
spectrophotometer) at wavelength λ=311nm. 
 
3.9 Cells and Cell culture tests 
3.9.1 Cell culturing 
PC 12 neuronal cell line was cultured in RPMI 1640 supplemented with 5% Fetal 
Bovine Serum (FBS), 10% horse serum (HS) (both heat inactivated), and 1% 
penicillin/streptomycin. Cells were grown in suspension in an incubator with 
humidified atmosphere with 5% CO2 at 37°C and an assessment made of their 
density, via haemocytometer and viability by trypan blue. 
 
3.9 .1.1 Assessment of cell density and cell viability 
Trypan blue (10µl) was mixed with 40µl RPMI 1640 media by shaking 
vigorously. 50µl of cell suspension was then added to the trypan blue solution and 
the mixture shaken well to mix and to debundle the neuronal cells. The suspension 
was introduced into one of the V-shaped wells with a Pasteur pipet. The area 
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under the cover slip was filled by capillary action. Enough liquid was introduced 
so that the mirrored surface was just covered. The charged counting chamber was 
then placed on the microscope stage and the counting grid brought into focus at 
low power. Cells were counted systematically in the four large corner squares and 
the middle one so that the total count was at least 100 cells.  
Calculations: The number of cells counted in the 5 fields was 154± 5 cells. Since 
each square has a surface area of 1mm
2
 and a depth of 0.1mm, giving it a volume 
of 0.1mm
3
, therefore 5 squares have a volume of 0.5mm
3
.Diving by the volume of 
the field (154 cells/0.5mm
3
) will give 308 cells/mm
3
 or 308000 cells/ml. Since the 
cells were diluted by a factor 50 the total number of cells was therefore (308000x 
50) 15 400 000 cells/ml. 
3.9.2 Cellular uptake 
3.9.2.1 Transfection of the cells 
For the translocation test, cell suspensions were prepared at a final concentration 
of 10 000cells/ml in 1ml media containing FITC labelled riluzole loaded CNTs. 
The concentrations of MWCNT-riluzole-FITC were 0.002, 0.02 and 0.2mg/ml. 
Untreated cells and unconjugated FITC were used as controls. The cells were 
incubated at 37
o
C for 1 hour. After incubation the cells were washed twice in 
phosphate buffered saline (PBS).  
 
3.9.2.2 Cell Fixation 
The cells were fixed in 0.5ml, 2% (wt: vol) paraformaldehyde in PBS, pH 7.4 for 
15 minutes in a microcentrifuge tube. The paraformaldehyde was then aspirated 
and the cells washed 3 times with PBS. The cells were gently pelletised by gentle 
centrifuging between washes. The cells were resuspended in 50µl of fluorescence 
mounting media (below) and 15µl was then applied on to a Poly-d-lysine coated 
slide to aid in the adherence of the cells to the surface. A non poly-d-lysine glass 
slide was then applied over the cells and all edges of the coverslip sealed to the 
glass slide with nail polish. 
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Fluorescence mounting media: 50ml of Glycerol and PBS (50:50, % vol) was 
placed in a flask and mixed on a stirrer for 15 minutes. The pH of the mounting 
media was then adjusted to 7.4 using 10M NaOH. 
 
3.9.2.3 Cell visualisation by fluorescence microscope 
The mounted coverslips were viewed on a Zeiss LSM 510 Meta Fluorescent 
microscope operating at 490nm excitation wavelength and detection wavelengths 
of 505-550nm band-pass filter to analyse the distribution of fluorescence. 
 
3.9.2.4 Quantitative Fluorescence determination  
After two washes with 1ml of phosphate buffered solution the cells were 
resuspended in 300µl PBS, loaded on to a 96 well plate and analysed with the 
victor X3 UV-vis mode at a wavelength of 492nm. The distribution of FITC was 
given in terms of absorbance units. The media and untreated cells were used as 
controls. 
 
3.9.3 In vitro cell viability and neuronal injury tests 
3.9.3.1 Cell viability after translocation 
To determine if the entry of the FITC labelled riluzole loaded MWCNTs entered 
the cells in a non-invasive way, cell viability using the CytoTox-Glo™ Assay 
(Promega, Madison, USA) was conducted. This assay uses a luminogenic peptide 
substrate (alanyl-alanylphenylalanyl-aminoluciferin; AAF-Glo™ Substrate) to 
measure “dead-cell protease activity” which has been released from cells that 
have lost membrane integrity. The CytoTox-Glo™ Assay relies on the properties 
of a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), 
which uses aminoluciferin as a substrate to generate a stable "glow-type" 
luminescent signal. The intensity of the signal is directly proportional to the 
number of dead cells. For the cytotoxicity test PC12 neuronal cell suspensions 
were prepared at a final concentration of 100,000cells/ml in media containing 
MWCNT-DEA-riluzole-FITC and its precursors (ox-MWCNT, MWCNT-DEA, 
and riluzole-MWCNT-DEA). Concentrations used were 0.002, 0.02 and 
0.2mg/ml. Apart from the test compound control, the following controls were also 
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used 1) No-cell background control and 2) untreated cells (maximum) viability 
control. The cells were incubated at 37
o
C for 1 hour. 
3.9.3.2 Physiochemical effects of drug-loaded CNTs on cell toxicity 
To determine the correlation between the physiochemical effects of drug-loaded 
MWCNTs and cell toxicity, PC12 neuronal cell suspensions were prepared at a 
final concentration of 100,000cells/ml in media containing riluzole-MWCNT@40, 
riluzole-MWCNT@60 and riluzole-MWCNT@100. Concentrations used were 0.002, 
0.02 and 0.2mg/ml. Apart from the test compound control the following controls 
were also used, 1) No-cell background control and 2) untreated cells (maximum) 
viability control with the same solvent used to deliver the test compounds to the 
untreated-cells control wells. The cells were incubated at 37
o
C for 24 hours in a 
96 well plate. After incubation, all the cultures were gently centrifuged and 
sample supernatants collected and in white-walled 96 well plates. CytoTox 96® 
Non-Radioactive Cytotoxicity Assay and reagents (Promega, Madison, USA) to 
quantitatively measure lactate dehydrogenase (LDH) were prepared and added as 
directed by the manufacturer. 
 
Released LDH in culture supernatants was measured with a 30-minute coupled 
enzymatic assay, which results in the conversion of a tetrazolium salt (INT) into a 
red formazan product which is catalyzed by the LDH released from cells and 
diaphorase present in the assay substrate mixture. The amount of color formed 
was proportional to the number of dead cells. Visible wavelength absorbance data 
was then collected using a standard 96 well plate reader at 490nm wavelength 
(formazan is detected at wavelength of 490nm). The data was presented as a 
percentage of the untreated cells control. 
 
3.9.4 Neuroprotective effects of riluzole loaded MWCNT  
Excitatory amino acids (e.g. glutamic acid) are neurotransmitters that play an 
important role in the development of chronic neurodegenerative disorders like 
Amyotrophic Lateral Sclerosis (ALS). Indeed, “excitotoxicity” is a term coined to 
describe an excessive release of glutamate, and a subsequent over activation of 
excitatory amino acid receptors (NMDA, AMPA, and kainate). Riluzole or 2-
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amino-6-(trifluoromethoxy) benzothiazole possesses neuroprotective effects one 
of which is reducing neuronal death due to glutamic acid induced neurotoxicity. 
The riluzole loaded MWCNTs were tested for their ability to counteract the 
glutamic excitotoxic cascade by means of an in vitro model of neuronal cells, and 
their effects were compared to those of riluzole as the reference drug. The 
protocol by Jin et al., (2000) was used with minor modifications. Tissue damage 
and protection were assessed by measuring the release of lactate dehydrogenase 
(LDH), which was taken as an index of overall cellular injury. 
 
3.9.4.1 Treatment of Neuronal Cultures with Glutamate  
Cultured PC12 neuronal cells were pre-incubated with riluzole-MWCNT@100 and 
free riluzole as a control for 1 hour at room temperature before Glutamic acid 
(Glu) treatment. Riluzole-MWCNT@100 and free riluzole were present throughout 
the Glu treatment at concentrations 0.1, 1 and 10µM. For Glu treatment, cultured 
neurons were stimulated with 0.25mM Glutamic acid for 5 minutes. The 
stimulation was terminated by removal of the Glu-containing medium. Cultures 
were further washed twice and incubated with serum-free RPMI 1640 for 24 
hours at 37
o
C to allow the process of neuronal injury to be completed. Controls 
used included acid oxidised MWCNTs, free riluzole, untreated cells for 
spontaneous LDH release correction and cells treated with Glu in the absence of 
the test materials for maximum LDH release. 
 
3.9.4.2 Determination of Neuronal Injury by Lactate Dehydrogenase Assay 
CytoTox 96® Non-Radioactive Cytotoxicity Assay and reagents to quantitatively 
measure lactate dehydrogenase (LDH) were prepared and added as directed by the 
manufacturer. The cultures were gently centrifuged and sample supernatants 
(50μl) collected and transferred to a fresh 96 well enzymatic assay plate. 
Reconstituted Substrate Mix (50μl) was added to each supernatant sample, and the 
enzymatic reaction was allowed to proceed for 30 minutes at room temperature, 
protected from light to allow for the conversion of a tetrazolium salt (INT) into a 
red formazan product. The enzymatic assay was then stopped by adding 50μl/well 
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of the Stop Solution (provided by supplier). Visible wavelength absorbance data 
was then collected using a standard 96 well plate reader at 490nm wavelength 
(formazan is detected at wavelength of 490nm).The data was presented as a 
percentage of the cells treated with Glu in the absence of riluzole-MWCNT@100 
and riluzole). 
 
3.10 Statistical Analysis on the cell culture tests 
A two-way between-groups analysis of variance (ANOVA) was conducted to 
explore the impact of MWCNTs test samples and their concentration on 
cytotoxicity, as measured by the LDH assay at 95% confidence level. The 
distribution used for the hypothesis test was the F distribution, based on the 
hypothesis test for the ANOVA. The F statistic is a ratio (a fraction). There are 
two sets of degrees of freedom; one for the numerator and one for the 
denominator. To calculate the F ratio, two estimates of the variance were made  
 
   1. Variance between samples (Mean square, MSbetween): An estimate of the 
variance of the sample means explained by the different groups (also called 
variation due to treatment). 
   2. Variance within samples (MSwithin): An estimate of the average of the sample 
variances due to chance (also known as variation due to error). 
 
The F ratio is therefore given by the Equation 3.1  
within
between
MS
MS
F                                                                                                     3.1 
The null hypothesis says that all the group population means are equal.  The 
hypothesis of equal means implies that the populations have the same normal 
distribution because it is assumed that the populations are normal and that they 
have equal variances. If the Null hypothesis is true then the F-ratio should be 
approximately equal to 1 because MSbetween and MSwithin both estimate the same 
value. If the null hypothesis is false, then the F-ratio will be larger than 1. Detailed 
statistical calculations are given in Appendix B4. 
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4. RESULTS AND DISCUSSION 
4.1 Physiochemical characterization of the riluzole loaded MWCNTs and its 
precursors 
From the TEM images below (Figure 4.1-4.4) both as-prepared and acid treated 
MWCNTs were free of amorphous carbon; neither loosely bound clusters nor a 
thin layer attached to the outer surface of MWCNTs could be observed.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 TEM images for as-prepared MWCNTs (unpurified)  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 TEM images for MWCNT@40 
54 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 TEM images for MWCNT@60 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 TEM images for MWCNT@100 
 
The TGA of purified samples, which was carried out in air, revealed a significant 
drop of mass at about 650 up to 800ºC. This weight loss was correlated with the 
decomposition of MWCNTs via oxidation (inflexion point of TGA curve, Figure 
4.5), as the characteristic combustion temperature of disordered carbon usually 
emerges at around 400ºC (Ramesh et al., 2006). This result complemented the 
TEM result that amorphous carbon was absent from both the as-prepared and acid 
oxidized MWCNTs. 
 
 
55 
 
200 400 600 800 1000
0
20
40
60
80
100
ox-MWCNT
@100
ox-MWCNT
@60
%
 M
a
ss
Temperature/
o
C
As preapred MWCNTs
ox-MWCNT
@40
 
Figure 4.5 Thermal stability for the ox-MWCNTs and as-prepared MWCNTs 
 
Table 4.1 below shows the qualitative information on the MWCNT purity 
obtained from the TGA based on the extent of non-oxidizable residue at high 
temperature and the temperature of oxidation. This residue is the metal catalyst 
which could not be oxidised at temperatures of 900ºC. Acid treatment at 100
o
C 
was the most effective means in removing metal impurities as it had 0% residue 
whilst the residual masses of ox-MWCNT@40 and ox-MWCNT@60 in thermo-
gravimetric analysis were 18 and 10, respectively (Table 4.1). It was observed that 
the higher the temperature of oxidation the lower the residual metal.  
Table 4.1 Thermal stability and metallic residue for the as prepared MWCNTs 
and acid treated MWCNTs 
Sample Inflexion 
temperature (
o
C) 
Residual mass (%) 
Unpurified 800 20 
Ox-MWCNT@40 720 14.8 
Ox-MWCNT@60 640 9.7 
Ox-MWCNT@100 680 0 
 
The lower inflexion temperature of the acid treated CNTs compared to the as-
prepared CNTs is due to the defects and functionalization moieties on carbon 
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nanotube walls. The excellent thermal stability (T>550
o
C) however indicates that 
the carbon nanotubes are not significantly damaged by the purification process. 
 
TEM imaging (Figure 4.1-4.4) confirms the reduction of catalytic metal 
aggregates. The catalyst particles and support material, which show dark contrast, 
are thickly covered with CNTs for as prepared MWCNTs (Figure 4.1) but they 
were significantly reduced for the acid oxidised MWCNTs (Figure 4.2-4.4). Most 
of the dark spots on the acid treated CNTs’ images are due to carbon nanotube 
endings aligned parallel to the electron beam.  
 
The harsh chemical conditions necessary for introducing functional groups 
affected the physical properties by cleaving the CNTs and introducing structural 
defects. The modal length of the large bundles was observed to be 1784, 1217 and 
760nm following a standard functionalization procedure of sonication in a mixture 
of H2SO4 and HNO3 at 40, 60 and 100
o
C respectively (Figure 4.6).  
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Figure 4.6 Length distribution of ox-MWCNT 
 
The size, percentage of residual material and morphology of the acid treated 
MWCNT samples were not affected by the amidation sequence yielding the drug 
loaded MWCNTs (Figure 4.7). However a decrease in the agglomeration was 
observed as the occurrence of CNTs clusters on TEM images reduced. 
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Figure 4.7 TEM images of a) riluzole-MWCNT@40 b) riluzole-MWCNT@60 
c) riluzole-MWCNT@100.  
 
The Raman analysis showed that there was no significant change that occurred to 
the structure due to the acid functionalization or conjugation of the drug to the 
CNTs as there was a similarity in the peaks as shown in Figure 4.8. The D-band is 
at 1355cm
−1
, only 30cm
−1
 broad, giving convincing indication for MWCNT 
origin. The D band represents the sp
3
 bonds (tetrahedral configurations) while the 
G band is attributed to a C-C stretching mode of well graphitized CNTs and sp
2
 
bonds (planar configurations). The increase in the ratio of the D band intensity to 
the G band intensity (ID/IG) was the key evidence for sidewall functionalization, 
due to the increased sp
3
-content in the sp
2
 framework of the CNT sidewalls. 
50nm 50nm 
200nm 150nm 
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Figure 4.8 Raman graphs for as prepared MWCNTs, acid treated MWCNTs and drug loaded 
MWCNTs at a) 40
o
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C c) 100
o
C 
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Indeed, the introduction of functional groups increased the ID/IG ratio of the 
samples. The D band intensity represents the existence of defects and other 
disorder-induced effects which were introduced and/or increased during the acid 
oxidation of the MWCNTs. The increase in the ratio of the D band intensity to the 
G band intensity (ID/IG) from 0.886 for unpurified CNTs to 0.898 for ox-
MWCNT@40, 1.01 for ox-MWCNT@60 and 1.04 for ox-MWCNT@100 was the key 
evidence for sidewall functionalization and reduction in structural order. The 
same trend was observed for the drug loaded MWCNTs (Table 4.2) verifying the 
increase in functionalisation due to the conjugation of riluzole. 
Table 4.2 (ID/IG) ratios for drug loaded MWCNTs 
Sample (ID/IG) 
Riluzole-MWCNT@40 
Riluzole-MWCNT@60 
Riluzole-MWCNT@100 
0.91 
1.02 
1.227 
The BET analysis showed that there was an increase in surface area from riluzole-
MWCNT@40 to riluzole-MWCNT@100 (Table 4.3). This may be explained by the 
fact that as the temperature of oxidation increased agglomeration and length were 
reduced. As agglomeration (number of tubes in a bundle) and length decrease the 
surface area is known to increase. This is in agreement with what Peigney et al., 
(2001) reported. They calculated the external surface area of CNTs and found that 
as the number of CNTs making a bundle decreased surface area increased.  
Table 4.3 Surface area for the drug-loaded MWCNTs 
 
Sample Surface Area 
(m
2
/g) 
Pore volume (cm
3
/g) 
Riluzole-MWCNT@40 32.6 0.167 
Riluzole-MWCNT@60 55.2 0.246 
Riluzole-MWCNT@100 75.3 0.301 
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The acid treatments produced carboxylic acid groups (COOH) and/or hydroxyl 
groups (OH) on surface of CNTs via oxidations of double bonds in the graphene 
wall as confirmed by the FTIR (Figure A5-A7). The peaks at around 3400cm
-1
 
corresponded to the infrared absorption of the H-bonded hydroxyl groups and 
around 1540cm
-1
 corresponded to the H-bonded carbonyl groups (C=O) that 
conjugate with C=C in the graphene wall. The peak at around 1735cm
-1
 
corresponds to the C=O stretch of acid carboxyl. The formation of amide 
functionalities in MWCNT-riluzole conjugate, was evidenced by the 
disappearance of the 1735cm
−1
 (C=O stretch of carboxyl) and the appearance of 
1670cm
−1
 (C=O stretch of amide carbonyl). Peaks at 1548cm
−1
 are attributed to 
the stretch of C–N and bend of N–H in amide). The peaks at 1113cm−1 
(corresponding to C–O–C ether group), 900cm-1 (corresponding to C-F stretch) 
adsorptions and 3033cm
-1 
(corresponding to aromatic C-H stretching), represent 
functional groups in the riluzole structure (Figure A10). 
 
The success of conjugation was further confirmed by a UV-vis analysis of the 
riluzole loaded MWCNTs. Free riluzole in methanol has an absorption peak at 
290-310nm wavelength (Figure 4.9) whilst acid oxidised MWCNTs have an 
absorption peak at 220nm (Figure 4.10) 
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Figure 4.9 UV spectra unconjugated riluzole 
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Figure 4.10 UV spectra for acid oxidised MWCNTs 
 
The UV/Vis spectrum of riluzole loaded MWNTs in methanol exhibit the typical 
absorption bands of both riluzole in the range 280-290 nm and those of oxidised 
MWCNTs at 220nm (Figure 4.11).This verified the presence of riluzole in the 
riluzole-MWCNT conjugate and therefore the success of conjugation. 
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Figure 4.11 UV/Vis spectra of riluzole-MWCNT  
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4.2 Quantitative loading of carboxylic functional group 
Table 4.4 tabulates concentrations of the COOH groups on the acid treated CNTs 
as a function of acid treatment conditions. As can be seen in Table 4.4 the 
concentrations of the COOH groups increase, with increasing temperature. 
Table 4.4 Contents of COOH groups of the acid-treated CNTs as a function of 
treatment conditions 
Sample Titre Vol 
of HCl/ml 
Equivalent moles 
 of COOH 
[COOH] 
mmol/g CNT 
Ox-MWCNT@40 4.5 0.0000055 0.11 
Ox-MWCNT@60 4.1 9.9E-06 0.198 
Ox-MWCNT@100 3.7 0.00001781 0.3562 
 
This is in agreement with what Shieh et al., (2007) observed after treating CNTs 
with a mixture of sulphuric and nitric acid at varying temperatures (25-80
o
C) for 
different time intervals. They found that the degree of carboxylic function loading 
increased in a temperature dependant manner with the CNTs treated at 80
o
C for 3 
hours with loading as high as 8.8mmols/g of CNTs. 
 
4.3 Dispersibility of riluzole loaded MWCNTs 
The riluzole-MWCNTs, derivatized by carbodiimide activated amidation at the 
carboxylic groups, formed homogeneous suspensions. The riluzole loaded 
MWCNTs had substantial dispersibility in chloroform, dichloromethane, and 
dimethylformamide. Indeed the black-colored (unsaturated) solution did not 
precipitate upon prolonged standing (Figure 4.12(a)). The drug loaded MWCNTs 
were insoluble in the more polar solvents; water, ethanol, and acetone (Figure 
12(b)). This may be explained by the fact that the lone pair on the nitrogen in the 
amide bond formed is delocalized over the O-C-N moiety and the ring in the 
riluzole structure making the conjugate non polar and consequently more 
dispersible in less polar solvents. Furthermore, the conjugate has a greater 
hydrophobic nature due to the high number of carbons and this reduces the ability 
of the amide bond to form hydrogen bonds with the polar solvents. 
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Figure 4.12 Pictures of a) DMF solution b) Water solution of the drug-loaded MWCNTs. The 
pictures was taken 1 month after the solutions had been sonicated for 5 min. 
 
This is consistent with what was reported by Chen et al., (1998). In their study, 
semiconducting single-walled carbon nanotubes (s-SWCNTs) derivatized with 
thionyl chloride and octadecylamine formed stable suspensions in organic 
solutions. The solubilities of s-SWCNTs in 1, 2-dichlorobenzene and CS2 were >1 
mg/ml and they did not observe precipitation with prolonged standing. Dumortier 
et al., (2006) reported a similar result when they found that conjugates that result 
from amidation formed stable suspension in water and organic solvents. 
 
4.4 Conjugation efficiency of riluzole 
The concentration of riluzole was seen to decrease as the reaction progressed as is 
shown on the concentration–time curve in Figure 4.13. This verified that 
conjugation was taking place. The reaction was stopped at 180 minutes because 
after longer times the drug-loaded MWCNTs formed a grey solution, making it 
difficult to obtain absorbance values that are comparable with the ones for clear 
solutions. This may be due to the fact that as more amide bonds are formed 
between the riluzole and the ox-MWCNTs the conjugate becomes more 
dispersible in DMF.  
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Figure 4.13 Variation of concentration of riluzole (in terms of absorbance) against 
time 
 
The conjugation efficiency was calculated using the following equation 4.1 
 
conjugatedbecanthatriluzoleimummax
conjugatedriluzole
conjugated%                             4.1 
 
Where the maximum that can be conjugated is the riluzole required at 1 x 
[COOH] equivalent concentration. The conjugation efficiency increased with 
initial concentration (Figure 4.14), there was loading of 42, 77, 92 and 96% at 0.5 
x [COOH], 1 x [COOH], 1.5 x [COOH] and 1.7 x [COOH], respectively. The 
optimal initial concentration was 1.7 x [COOH] which had a conjugation 
efficiency of 96% within the 180 minutes of reaction (Figure 4.14). 
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Figure 4.14 Conjugation efficiency of riluzole at the various initial concentrations 
A plot of the amount of riluzole conjugated against time for the different initial 
concentrations (Figure 4.15) that were used showed that the amount of riluzole 
conjugated increased with the initial concentration. The concentration of riluzole 
was calculated from the absorbance values using the riluzole calibration curve 
(Figure A1).  
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Figure 4.15 A plot of the degree of riluzole conjugation against time: smooth lines 
represent model while marked lines represent the experiment 
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16mg of riluzole was attached per gram of oxidised carbon nanotubes for the 
highest equivalent concentration of 1.7x [COOH] and there was a decrease as the 
equivalent concentration decreased. The equation used to model the degree of 
conjugation was  
               )1(
BteAconjugatedRiluzole                                                      4.2 
Where A and B are constants for one initial concentration but vary with change in 
concentration and are given in Appendix 4. 
 
4.5 Rate law determination 
The concentration of riluzole ([riluzole]) grew exponentially with time showing 
that the reaction is first order with respect to riluzole (Equation 4.3). 
 
              [riluzole] = [riluzole] 0 e
- k t                                                     
                             4.3 
 
Where k is the rate constant (s
-1
) and t is the time (seconds). This equation 
describes the integrated law for a first order reaction. To confirm this finding a 
characteristic kinetic plot for first order (ln [concentration of riluzole] against 
time) was plotted. The kinetic plot of ln [initial concentration of riluzole] against 
time produced straight lines for all four initial concentrations (Figure 4.16).  
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Figure 4.16 Plot of ln (initial concentration of riluzole) against time  
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Combining the two findings the rate law is therefore first order with respect to the 
riluzole concentration (Equation 4.4) 
 
                  ][riluzolekrate                   4.4 
 
Where k is the rate constant and is given in Table 4.5 for each initial concentration 
 
Table 4.5 Rate constant for the different initial concentrations 
Initial concentration Rate constant (sec
-1
) 
0.5 x [COOH] 0.25 
1.0 x [COOH] 0.175 
1.5 x [COOH] 0.14 
1.7 x [COOH] 0.0931 
 
4.6 Labelling of the drug loaded MWCNT with FITC  
The UV/Vis spectrum of riluzole-MWNTs-DEA in methanol exhibited the typical 
absorption bands of riluzole in the range 290nm, DEA at 250nm and ox-MWCNT 
at 220nm verifying the success of conjugation (Figure 4.17) 
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Figure 4.17 UV/Vis spectra of riluzole-MWCNT, MWCNT-DEA and riluzole-MWCNT-DEA 
in methanol 
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The success of the amidation of DEA and riluzole was also verified by the FTIR 
analysis through the appearance of three major peaks at ~1638cm
-1
(C=O amide 
stretch), ~1517cm
-1
(C-N stretch) and ~3200cm
-1
(N-H stretch) (Figure A8). The 
peaks at ~3030cm
-1
 represent the aromatic, whilst the peak 1400cm
-1
 represents 
the C-H bend which are present in the riluzole structure verifying the presence of 
riluzole in the conjugate. The presence of DEA was verified by the peak at 2800-
2900cm
-1
 which is characteristic for the aliphatic C-H stretch. (Figure A9) 
 
The HNMR spectra verified the successful deprotection of the amino groups 
before the conjugation of the FITC (Figure A10). The 1H NMR spectrum of 
MWCNT-DEA-Boc in CDCl3 showed the presence of the Boc group (d=1.4 
ppm), and this was seen to disappear after deprotection (Figure A11). The analysis 
of the FITC loaded drug-loaded MWCNT (Figure 4.18a) also showed the 
presence of FITC through the appearance of characteristic bands in the range 430-
490nm (Figure 4.18b). 
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Figure 4.18 UV spectra for a) FITC b) riluzole-MWCNT-DEA-FITC in methanol 
a 
b 
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4.7 Uptake of FITC labelled CNT-riluzole by PC12 neuronal Cells
 
It is evident that riluzole-MWCNT-FITC accumulates into the cell (visualised as 
green fluorescence, in Figure 4.19 (a-c) suggesting that they have been actively 
captured by the cells or that they have diffused through the cell membrane. The 
fluorescence signal is proportional to the dose. The best results in terms of number 
of stained cells and fluorescence intensity were obtained when the cells were 
cultured with 0.2mg/mL of riluzole-MWCNT-FITC for the one hour period 
(Figure 4.19c).  
 
Figure 4.19 shows representative images corresponding to the PC12 neuronal cells after being 
treated with a) 0.002mg/ml, b) 0.02mg/ml, and c) 0.2mg/ml concentrations of riluzole-
MWCNT-FITC for 1 hour.  
 
The result is consistent with what has been reported in literature that CNTs are 
able to translocate across the cellular membrane. Dumortier et al., (2006) prepared 
two types of functionalized CNTs, following the 1,3-dipolar cycloaddition 
reaction and the oxidation/ amidation treatment, respectively. They found that 
both types of functionalised CNTs are up taken by B and T lymphocytes as well 
as macrophages in vitro, without affecting cell viability. CNT-riluzole-FITC was 
detected as big bundles in the medium (as indicated by the arrow in Figure 4.20) 
this may possibly be due to the presence of some aggregates, which settled in the 
cell culture which were a result of the stable suspensions the riluzole-MWCNT-
FITC formed in the cell culture media  
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Figure 4.20 Aggregates of riluzole-MWCNT-DEA-FITC on the cell membrane 
After the incubation the cells were washed by centrifugation and the fluorescence 
intensity for both the cells and the supernatant was determined by the Victor X3 
(Table 4.6 and 4.7). 
Table 4.6 Fluorescence intensity data inside the cells 
Inside cells 
  Fluorescence intensity Mean SD 
0.02mg/ml 84714 73699 79929 79447.3 4509.73 
0.02mg/ml 65603 51607 57053 58087.7 5760.49 
0.2mg/ml 42089 47205 54268 47854.0 4993.19 
FITC only 32941 26679 30322 29980.7 2567.82 
Cells 27243 31102 30365 28804.6 1672.72 
Table 4.7 Fluorescence intensity data for the supernatant 
Supernatant 
  
0.02mg/ml 
Fluorescence intensity Mean 
3201.07 
SD 
306.49 2940.97 3631.40 3030.84 
0.02mg/ml 5729.40 4921.96 5768.26 5473.21 390.11 
0.2mg/ml 6090.36 5829.8 5979.58 5966.58 106.77 
FITC only 38190.0 41000.0 41460.0 40156.00 14453.22 
Cells 571.38 628.13 590.14 599.75 23.66 
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The translocation efficiency was then calculated as follows 
ceFluorescenTotal
cellsinsideensityceFluorescen
ionTranslocat
int
%                                    4.5 
Where, the total fluorescence is the sum of the fluorescence intensity for cells and 
for the supernatant. Both intensities are after background correction. The delivery 
efficiency in this experiment for the highest concentration of 0.2mg/ml was 95% 
(Figure 4.21), suggesting that all cells had taken up the CNT-riluzole-FITC 
conjugate. FITC only control was performed to corroborate these findings. Figure 
4.21 shows a low level of fluorescence, thus indicating that FITC only is able to 
enter cells to a very small extent, which demonstrates that CNTs play an 
important role as a delivery system in rapidly and efficiently delivering the drug 
into the cells.  
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Figure 4.21 Fluorescence intensities inside the cells 
 
4.8 Cell viability during cellular uptake of riluzole-MWCNT-DEA-FITC 
To assess the biological properties of the novel, doubly functionalized CNTs, the 
toxicity effects of MWCNT-riluzole-FITC on mammalian cells was initially 
studied, tracing its capacity to cross the cell membrane. The conjugation of 
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riluzole to CNTs clearly has not shown toxic effects on the PC12 neuronal cells. 
At all doses, all the cells remained alive upon treatment with MWCNT-riluzole-
FITC as compared to the untreated cells Figure 4.22. There was a statistical 
significance of the MWCNT samples, F=31.76 (Table B10) at 95% 
confidence level. 
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Figure 4.22 Relative cell viability after treatment of cells with FITC labelled drug loaded 
MWCNT and its precursors. Mean± standard deviation. Means are significantly different 
(P<0.05). 
 
4.9 Physiochemical effects of drug loaded MWCNTs on cell viability 
The three drug loaded MWCNT: riluzole-MWCNT@40, riluzole-MWCNT@60, 
riluzole-MWCNT@100 samples were modified according to routes that decoupled 
key physicochemical and structural properties, including length, catalytic metal 
content, aggregation state, and surface chemistry. Properties with suspected 
relevance cytotoxicity obtained from the TEM, BET analyser, Raman and 
Thermogravimetric analysis are summarized in Table 4.6. Average lengths of 
riluzole-MWCNT@40, riluzole-MWCNT@60, riluzole-MWCNT@100 were 
determined by TEM images, respectively (Table A2-A4). Residual mass (RM
b
, 
%) was the remaining non oxidizable mass that remained after thermo-gravimetric 
analysis (TGA). The ratio of Raman D band (1350cm
-1
) and G band (1580cm
-1
) ( 
ID/IG
c) peak height was determined at wavelength of 532nm. 
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Table 4.8 Summary of physiochemical properties of the drug loaded MWCNTs.  
Sample Length 
a
 
(nm) 
Surface Area 
m
2
/g 
RM
b
 
(%) 
ID/IG
c
 
riluzole-MWCNT@40 1784 32.6 14.8 0.91 
riluzole-MWCNT@60 1217 55.2 9.7 1.02 
riluzole-MWCNT@100 760 75.3 0 1.23 
 
In vitro studies to assess the cytotoxic capability of the riluzole-MWCNT 
supramolecular assemblies using the PC12 neuronal cells showed that short 
nanotubes with surface area (30-80m
2
/g) and with <10% metal impurities are not 
cytotoxic to neuronal cells (Figure 4.23). As displayed in Figure 4.23, there was no 
significant loss of cell viability upon incubation of the cell with 0.002-0.2mg/ml 
of drug loaded MWCNTs for 24 hours observed, as compared to untreated cells. 
There was a statistical significance of MWCNT samples, F=7.70 (TableB11) 
and concentration effect, F=7.92 (TableB11) at 95% confidence level.  
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Figure 4.23 Relative cell viability after treatment with the drug loaded MWCNTs. Mean± 
standard deviation. Means are significantly different (P<0.05). 
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The results showed that purification and functionalization modifications that alter 
the physicochemical properties of the MWCNTs have no effect on neuronal cell 
toxicity. The cell viability of the drug loaded MWCNTs was the same as that of 
the untreated cells control. The cytotoxicity of covalently modified CNTs has 
been reported to be further decreased with the increase in the degree of sidewall 
functionalisation Sayes et al., (2006). 
 
Long and rigid CNT (high aspect ratio) have been found to increase the risk of 
ROS generation and inflammatory response stimulation, (Sato et al., 2005; Kim et 
al., 2010). In this study the shorter riluzole-MWNT@100 did not display 
significantly higher toxicity than longer riluzole-MWCNT@40. This can be 
explained by the hypothesis that even though the riluzole-MWCNT@40 are longer 
relative to the other samples they still fall under the short range. Long tubes can 
be defined as tubes that significantly exceed the size of macrophages and are 
usually taken to be 10-20µm long (Sato et al., 2005). It is impossible to have 
longer tubes due to the acid oxidation step which was necessary to introduce the 
carboxylic groups which were a platform for the drug conjugation, however, 
shortens CNTs to as short as 140nm (Wu et al., 2005) depending on production 
conditions.  
 
Intrinsic toxicity of CNTs has also been shown to depend on the presence of 
impurities such as amorphous carbon and metallic nanoparticles (catalysts: Co, 
Fe, Ni and Mo) (Shevdova et al., 2003). However in this study catalytic metal (Fe) 
content in the MWNT samples does not significantly affect the toxicity of drug 
loaded MWCNTs samples. Indeed, riluzole-MWCNT@40 which had as much as 
15 % impurities, exhibited no toxicity in cell membrane integrity assays similar to 
the riluzole-MWCNT@60 which had 50% less metal impurities and riluzole-
MWCNT@100 which had 100% less content.  
 
The apparent inconsistency between data in this study and previous studies 
correlating residual catalytic metal in unpurified CNTs to elevated toxicity in 
human epidermal keratinocytes (Shvedova et al., 2003) may stem from the 
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relatively low  metal content of sample in this study (<15%, compared to 30% in 
the Shvedova et al., (2003) study. It would appear that the riluzole loaded 
MWCNTs with at least 30% metal residue are required to produce cytotoxic 
effects. Alternatively, residual catalytic metals may damage eukaryotic cell lines 
through pathways not affected in neuronal models. Pulskamp et al. (2007) 
reported a similar result to ones of this study. They observed a low cytotoxicity 
for raw SWCNTs (high iron contamination), purified SWCNTs (low iron), and 
purified MWCNTs (low iron) in rat alveolar macrophages. 
 
4.10 Effect of MWCNT-riluzole on Glutamic acid Induced Neuronal Injury 
In the Glutamic acid treated control, brief exposure of cultured neurons to 
0.25mM Glutamic acid was sufficient to cause marked neuronal damage as 
indicated from comparing the LDH released of untreated cells (60%) and that of 
Glutamic acid treated cells in the absence of riluzole or riluzole-MWCNT@100 
(100%) (Figure 4.24). The percentage relative neuronal death was calculated as 
follows 
 
releasedLDHMaximumreleaseLDHMeanreleaseLDH /%   4.6 
 
Where the maximum LDH release was taken to be the LDH released in the cells 
treated with Glutamic acid only in the absence of the drug loaded MWCNTs and 
riluzole. Absorbance values for LDH assay based on glutamic acid induced 
excitotoxicity for 0.1, 1 and 10 µM concentration of riluzole-MWCNTs is given 
in Tables B7-B9. There was a statistical significance of riluzole-MWCNT@100, 
riluzole and ox-MWCNTs, F=78.52 (Table B12) at 95% confidence level. The 
main effect for concentration did not reach statistical significance, F=1.016 
(TableB12) at 95% confidence level.  
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Figure 4.24 Relative LDH release percentage. (*)means are significantly different (P<0.05) 
 
Glu at 0.25mM increased LDH release by about 40% above the control whereas in 
riluzole-MWCNT@100 protected groups and riluzole, LDH release was reduced to 
less than that of the untreated cells control. The riluzole had 60, 43, 40% LDH 
released for the 10, 1 and 0.1µM concentration respectively and riluzole-
MWCNT@100 53, 53,42% LDH released for the 10, 1 and 0.1µM concentration 
respectively compared to untreated cells which had 63% release. In the group 
treated with Glutamic acid in the presence of 0.1µM riluzole-MWCNT@100 
(Figure 4.26), the neuronal viability appears to be best preserved (Figure 4.24), 
with an LDH release of 42% compared to the 53% for the 10µM and 1µM. The 
antiglutamic activity of 0.1µM riluzole-MWCNT@100 (42% LDH released) is 
comparable to that of free riluzole (40% LDH released).  
 
This suggests that 0.1µM riluzole-MWCNT@100 may have protective function 
against Glu-induced neuronal injury which is comparable to that of riluzole. 
Furthermore, the neuroprotective function of riluzole-MWCNT@100 against Glu-
induced neurotoxicity appears to be dose-dependent reducing LDH release from 
53% to 42% at 10, 1 and 0.1uM riluzole-MWCNT@100 respectively (Figure 4.26). 
This is consistent with results that have been reported on the antiglutamic effect of 
* 
* 
* 
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riluzole and the optimal concentration necessary for effective preservation of cells 
from excitotoxicity. Azbill et al., (2000) found out that the rate of glutamate 
uptake was significantly increased in the presence of 0.1µM and 1.0µM riluzole, 
but not at the higher concentrations examined. 
. 
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5 CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
CNTs were oxidized using strong acids, resulting in the reduction of their length 
while generating carboxylic groups, which increase their dispersibility in aqueous 
solutions. According to the results, the best length and loading of the carbon 
nanotubes was achieved at 100
o
C temperature as they exhibited the most 
convenient length and loading. The drug molecule riluzole has been attached to 
carbon nanotubes via carbodiimide activated amidation between the amine groups 
on riluzole and the carboxylic acid groups on MWCNTs. UV/vis and FTIR 
analysis confirmed that riluzole molecules were successfully conjugated to the 
surface of acid-functionalized carbon nanotubes. The amine terminated riluzole 
forms an amide link with the carboxylic group on the acid oxidised CNTs as 
shown by the FTIR. This approach provides an efficient method to conjugate 
therapeutic molecules like riluzole to carbon nanotubes for further delivery 
purposes. 
 
There was a high conjugation efficiency (96%) of the drug to the CNTs for the 
1.7x [COOH] equivalent concentration of riluzole within 3 hours of reaction. The 
rate of conjugation was determined to increase with the concentration of riluzole. 
The riluzole-CNT conjugate was seen to rapidly cross the cell membrane of the 
neuronal cells as indeed high fluorescent intensities were observed within 1 hour. 
The cellular activity of riluzole-MWCNT conjugate was shown to preserve the 
anti-glutamic action of riluzole.  
 
The data from this study supports the hypothesis that physiochemical 
modifications of MWCNTs that occur due to the functionalisation of the drug to 
its surfaces alter their toxicity in neuronal systems. The riluzole loaded MWCNTs 
with <15% metallic residue, 500-2000nm length, and surface areas (30-76 m
2
/g) 
were found not to cause toxic effects as all the cells were viable compared to the 
untreated cells control. This suggests that covalently linking riluzole to MWCNTs 
and the consequent changes in the physiochemical properties does not lead to the 
generation of toxic effects in cells.  
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The rapid internalisation of the riluzole by carbon nanotubes in a non-toxic 
manner coupled with the neuroprotectiveness will be particularly advantageous 
for an improved efficiency of the drug action. This conclusion underlines the need 
for careful documentation of physical and chemical characteristics when reporting 
the toxicity of carbon based drug delivery systems. The identification of specific 
physiochemical properties governing CNTs toxicity presents the opportunity for 
carbon nanotube based drug delivery systems designs or applications that reduce 
human and environmental impacts. 
 
5.2 Recommendations 
In this study it has been shown that it is possible to multifunctionalise the surface 
of CNTs with different molecules i.e. riluzole and FITC were successfully 
conjugated to the same CNT surface. The concept of imparting multiple chemical 
species, such as solubility enhancers, drugs, fluorescent tags, with different 
functionalities onto the surface of the same nanotube should open up new 
opportunities in chemical, biological, and medical applications of novel 
nanotubes. Given that multiple pathogenic processes likely underlie motor neuron 
degeneration in ALS, more effective disease-modifying strategies are likely to 
arise from the combined use of other pharmacological agents along side riluzole. 
A study on the efficacy of CNTs loaded with a combination of neuroprotective 
drugs could be the answer in overcoming the current short falls in the treatment of 
ALS. 
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APPENDIX A  
A1 DETAILED RESULTS FOR THE LENGTH DISTRIBUTION 
Table A1 TEM scale conversion based on magnification  
Magnification 1mm=nm 
15 6.66 
20 50 
25 40 
30 33.33 
40 25 
50 20 
100 10 
200 5 
Table A2 Length distribution for ox-MWCNT@40 
Magnification Length/mm 
Actual 
length/nm 
30 185 6166.05 
15 110 732.6 
25 36 1440 
15 55 366.3 
25 49 1960 
25 51 2040 
25 39 1560 
40 63 1675 
40 25 1000 
40 70 2800 
40 10 400 
40 45 1800 
100 110 1100 
30 40 1333.2 
50 60 600 
50 60 1200 
50 110 2200 
15 25 1666.5 
30 75 2475 
30 165 1098.9 
30 40 1333.2 
30 65 2166.45 
25 70 1750 
100 180 1800 
100 160 1600 
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Table A3 Length distribution for ox-MWCNT@60 
Magnification Length/mm 
Actual 
length/nm 
50 35 700 
50 50 1000 
50 47 940 
50 25 500 
20 27 1350 
20 30 1500 
50 55 1100 
50 52 1040 
40 70 1750 
40 64 1600 
40 80 2000 
40 83 2075 
100 120 1200 
50 65 1300 
40 80 2000 
30 70 2333.1 
50 80 1600 
20 25 1250 
100 75 750 
25 80 3200 
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Table A4 Length distribution for ox-MWCNT@100 
Magnification Length/mm 
Actual 
length/nm 
50 40 800 
50 70 1400 
50 25 500 
100 85 850 
100 110 1100 
100 45 450 
25 74 2960 
30 44 1466.52 
30 29 966.57 
40 210 5250 
30 45 1499.85 
15 60 399.6 
15 30 999.9 
30 27.1 903.243 
100 120 1200 
20 40 2000 
20 53 2650 
20 14 700 
20 30 1500 
30 30 999.9 
30 55 1833.15 
20 43 2150 
20 24 1200 
20 20 1000 
30 55 1833.15 
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A2 QUANTITATIVE ASSESSMENT OF CARBOXYLIC FUNCTIONAL 
GROUP LOADING CALCULATIONS 
 
Acid-base titrations were used and the following calculations were used to 
determine the quantity of carboxylic groups on the surface of the MWCNTs 
 
Molarity for HCl 
Given  
ρ   = 1.19kg/L 
% = 37  
Mr = 36.36 
Then, Density = 1.16 kg/l thus you have 1160 g per l. Of these 1160 g per liter, 
32% (or 1160 * 0.32= 371.2 g) are HCl. By dividing 371.2 g/l of HCl by the 
molecular weight of HCl (36.36 g/mol), it is possible to calculate the molarity of 
your solution:  371.2g/l / 36.36 g/mol = 10.181mol/l. 
Using 
 C1V1 = C2V2                                                                                                           (A1) 
Then 
 V1= (0.01 x 1L)/ (10.47305) 
       = 0.0009822ml/ml water 
      = 0.9822 ml HCl per litre of water 
 
Molarity for NaOH 
Density = 1.349 kg/l thus you have 1.349 g per L. Of these 1.349 g per liter, 32% 
(or 1349 * 0.32 = 431.68 g) are HCl. By dividing 431.68 g/l of HCl by the 
molecular weight of NaOH 39.99 g/mol), it is possible to calculate the molarity of 
your solution:  440.3 g/l / 40.00 g/mol = 10.792mol/l. 
  
Then 
 V1= (0.04 x 1L)/ (10.792) 
       = 0.0009266ml/ml water 
      = V NaOH per litre of water 
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Carboxylic concentration on the nanotubes 
Given that  
       Mole = (Molarity x Volume) / 1000                                                        (A2) 
 
Therefore for        
» Moles of NaOH added to the carboxylated carbon nanotubes 
= (MNaOH x VNaOH) / 1000 
 = NaOH moles 
 
» Mol of HCl used for the titration of filtrate for  
 M= MHCl 
 V= Vtitre cm
-3
 
» Moles = (MHCl x Vtitre)/1000 
    = HCl moles 
 
» Moles of NaOH that are equivalent to COOH = NaOH moles - HCl moles 
        = [COOH] moles 
 
» COOH concentration on the nanotubes (mol COOH/g nanotube) 
   = [COOH] /mass of CNTs                                              (A3) 
   = [COOH] moles/g nanotube 
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A3 CALIBRATION CURVE FOR RILUZOLE 
Summary of Statistics 
Table A5 One sample t test 
Number of 
variables 
Mean Standard 
deviation 
t P value Standard 
error 
4 0.19025 0.10675 3.5645 0.03770 0.05337 
      
 
Null hypothesis:   Mean= 0 
Alternative hypothesis: Mean<> 0 
 
At the 0.05 level, the population mean is significantly different than the test mean 
(0).                                
                        
Linear Regression for Data 
         
                                 Y = A + B * X 
                                                                        
Table A6 Linear constants 
 
 
  
 
 
 
Table A7 Linear regression analysis                                                                                  
R Standard deviation Probability 
0.99028 0.11171 0.00115 
 
The coefficient of correlation (r) is almost equal to one therefore the data strongly 
correlates and can be used to predict concentrations of riluzole given an 
absorbance value. 
Parameter Value  Error 
A 0.04382 0.08411 
B 5.48345  0.44456 
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Figure A1 Calibration curve for riluzole 
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Figure A2 Error analysis for the calibration curve 
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A4 MODEL CALCULATIONS FOR THE DEGREE OF CONJUGATION 
The equation used to model the degree of conjugation was  
               )1(
BteAconjugatedRiluzole  
Where A and B are constants for one initial concentration but vary with change in 
concentration 
 
The % conjugated was calculated using the following equation 
]/[max][% conjugatedbecanthatriluzoleimumconjugatedriluzoleconjugated  
Where the maximum that can be conjugated is the riluzole required at 1 x 
[COOH] equivalent concentration. 
Table A8 Degree of loading of riluzole to ox-MWCNT@100 at 0.5 x [COOH] 
initial concentration 
Time/minutes 
A B 
0.07644 0.01153 
0.5 x [COOH] 
Riluzole 
conjugated/mg/ml 
% 
conjugated 
0 0 0 
15 0.012140226   
30 0.022352337 14.00288291 
45 0.030942557   
60 0.038168476 26.00003165 
75 0.044246772   
90 0.049359711 28.38199367 
105 0.053660611   
120 0.057278441 32.27680696 
135 0.060321686   
150 0.062881602 39.33413291 
165 0.065034951   
180 0.066846305 41.92863924 
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Table A9 Degree of loading of riluzole to ox-MWCNT@100 at 1.0 x [COOH] 
initial concentration 
Time/minutes 
A B 
0.14402 0.01052 
1.0 x [COOH] 
Riluzole 
conjugated/mg/ml 
% 
conjugated 
0 0 0 
15 0.021023958   
30 0.03897885 26.74271519 
45 0.054312697   
60 0.067408118 42.67681962 
75 0.078591877   
90 0.088143037 52.21016456 
105 0.096299925   
120 0.103266074 59.05677848 
135 0.109215309   
150 0.114296078 70.53417089 
165 0.118635159   
180 0.122340824 76.77368987 
Table A10 Degree of loading of riluzole to ox-MWCNT@100 at 1.5 x [COOH] 
initial concentration 
Time/minutes 
A B 
0.16113 0.01345 
1.5 x [COOH] 
Riluzole 
conjugated/mg/ml 
% 
conjugated 
0 0 0 
15 0.029438576   
30 0.053498701 36.03481013 
45 0.073163022   
60 0.089234657 55.57911392 
75 0.102369992   
90 0.113105491 67.12246835 
105 0.121879606   
120 0.129050683 74.02405063 
135 0.134911599   
150 0.139701721 87.33860759 
165 0.143616684   
180 0.146816381 91.61392405 
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Table A11 Degree of loading of riluzole to ox-MWCNT@100 at 1.7 x [COOH] 
initial concentration 
Time/minutes 
A B 
0.16431 0.01822 
1.7 x [COOH] 
Riluzole 
conjugated/mg/ml 
% 
conjugated 
0 0 0 
15 0.039292355   
30 0.069188513 45.57426266 
45 0.091935438   
60 0.109242765 63.18001582 
75 0.122411296   
90 0.132430764 81.67381329 
105 0.140054221   
120 0.145854639 88.02815506 
135 0.150267971   
150 0.153625919 95.49407911 
165 0.156180862   
180 0.158124828 96.27401899 
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A5 FTIR FOR ACID TREATED MWCNTs AT 40
o
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3 FTIR for acid treated MWCNTS at 40
o
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A6 FTIR FOR ACID TREATED MWCNTs AT 60
o
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4 FTIR for acid treated MWCNTS at 60
o
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A7 FTIR FOR ACID TREATED MWCNTs AT 100
o
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5 FTIR for acid treated MWCNTS at 100
o
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A8 FTIR FOR MWCNT-DEA-Boc 
 
 
 
Figure A6 FTIR for MWCNT-DEA-Boc 
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A9 FTIR FOR RILUZOLE-MWCNT-DEA 
 
 
Figure A7 FTIR for riluzole-MWCNT-DEA 
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A10 FTIR FOR riluzole-MWCNT 
 
 
Figure A8 FTIR for drug loaded MWCNTs 
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A11 HNMR FOR BOC PRESENCE 
 
 
Figure A9 HNMR of MWCNT-DEA-Boc.peak at 1.2 represents the Boc group 
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A12 HNMR AFTER BOC REMOVAL 
 
Figure A10 HNMR showing the successful cleavage of Boc 
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APPENDIX B 
B1 CELL VIABILITY FOR FITC LABELLED DRUG LOADED MWCNTS 
Table B1 Luminescence intensity for cells treated with 0.2mg/ml of test material 
  0.2mg/ml Mean SD 
Cells 6678 6538   6608 98.99495 
MWCNT-DEA 6418 6454 6116 6329 185.6269 
riluzole-MWCNT-
DEA 6764 6896 6736 6799 93.3381 
riluzole-MWCNT-
DEA-FITC 6276 6596 6541 6436 171.0994 
Media 262 268 164 231 58.3895 
            
Table B2 Luminescence intensity for cells treated with 0.02mg/ml of test material 
  0.02mg/ml Mean SD 
Cells           
MWCNT-DEA 5984 7174 5912 5948 50.9 
riluzole-MWCNT-DEA 6152 7086 6922 6720 498.7 
riluzole-MWCNT-
DEA-FITC 6198 5908 6050 6053 205.1 
Media 262 268 164 231 58.4 
            
Table B3 Luminescence intensity for cells treated with 0.002mg/ml of test 
material 
  0.002mg/ml Mean SD 
Cells           
MWCNT-DEA 6126 5956 6544 6209 302.591 
riluzole-MWCNT-DEA 6746 6672 7128 6709 52.3259 
riluzole-MWCNT-
DEA-FITC 6543 5879 6089 6170 339.3896 
Media 262 268 164 231 58.39 
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B2 CELL VIABILITY FOR THE EFFECT OF PHYSIOCHEMICAL 
PROPERTIES 
The Experimental LDH is the LDH released after media background subtraction 
and the higher the absorbance the higher the cell death 
Table B4 Absorbance values for LDH assay based on the physiochemical effects 
for 0.2mg/ml concentration of riluzole-MWCNTs 
  0.2mg/ml Mean 
experimental 
LDH SD 
riluzole-MWCNT@40 0.2549 0.2894 0.2577 0.267333 0.166 0.019162 
riluzole-MWCNT@60 0.2697 0.2832 0.2597 0.270867 0.1695 0.011793 
riluzole-MWCNT@100 0.2775 0.2901 0.2601 0.2759 0.174 0.015064 
Cells 0.2345 0.2852 0.3219 0.280533 0.179 0.043886 
Media 0.0976 0.1113 0.0952 0.101367   
 
Table B5 Absorbance values for LDH assay based on the physiochemical effects 
for 0.02mg/ml concentration of riluzole-MWCNTs 
  0.02mg/ml Mean 
experimental 
LDH SD 
riluzole-MWCNT@40 0.2574 0.2572 0.2779 0.264167 0.163 0.011894 
riluzole-MWCNT@60 0.2565 0.2897 0.2254 0.2572 0.156 0.032156 
riluzole-MWCNT@100 0.2627 0.274 0.3195 0.2854 0.184 0.030067 
 
 
 
 
 
 
 
123 
 
Table B6 Absorbance values for LDH assay based on the physiochemical effects 
for 0.002mg/ml concentration of riluzole-MWCNTs 
  0.002mg/ml Mean 
experimental 
LDH SD 
riluzole-
MWCNT@40 0.2586 0.2311 0.2485 0.246067 0.145 0.013911 
riluzole-
MWCNT@60 0.2564 0.2329 0.2508 0.2467 0.145 0.012275 
riluzole-
MWCNT@100 0.2587 0.2661 0.2737 0.266167 0.165 0.0075 
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B3 NEUROPROTECTIVENESS OF DRUG LOADED MWCNTs 
The percentage relative neuronal death was calculated as follows 
releasedLDHMaximumreleaseLDHMeanreleaseLDH /%  
Where the maximum LDH release was taken to be the LDH released in the cells 
treated with Glutamic acid only in the absence of the drug loaded MWCNTs and 
riluzole. 
Table B7 Absorbance values for LDH assay based on glutamic acid induced 
excitotoxicity for 10 µM concentration of riluzole-MWCNTs 
  10µM Mean SD 
riluzole-MWCNT@100 0.098135 0.09958 0.10598 0.10123 0.00417 
Ox-MWCNT@100 0.162718 0.18906 0.18404 0.17860 0.01398 
Riluzole 0.10071 0.14775 0.09329 0.11391 0.02953 
Cells 0.126655 0.11961 0.13062 0.12562 0.00557 
Cells +GLU only 0.18364 0.17908 0.20714 0.18995 0.01506 
media +GLU 0.07718 0.07236 0.07088 0.07347 0.00329 
Table B8 Absorbance values for LDH assay due to on glutamic acid induced 
neuronal injury for 1µM concentration of test materials 
  1µM Mean SD 
riluzole-MWCNT@100 0.09586 0.13247 0.10516 0.10051 0.00657 
Ox-MWCNT@100 0.22330 0.16588 0.15798 0.18239 0.03565 
Riluzole 0.08627 0.07765 0.07011 0.08196 0.00808 
Table B9 Absorbance values for LDH assay due to on glutamic acid induced 
neuronal injury for 0.1µM concentration of riluzole-MWCNTs 
  0.1µM Mean SD 
riluzole-MWCNT@100 0.1028 0.0715 0.06757 0.08067 0.01931 
Ox-MWCNT@100 0.1716 0.1781 0.1928 0.18089 0.01087 
Riluzole 0.0742 0.073 0.07829 0.075163 0.002773 
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B4 STATISTICAL ANALYSIS ON THE SIGNIFICANCE OF THE 
TOXICITY AND EFFICACY DATA  
A two-way between-groups analysis of variance was conducted to test the 
significance of the data at 95% confidence level. The following equations were 
used to calculate the terms in the ANOVA tables (Table B10-B12). 
N
totalGrand
CFfactorCorrection
2)(
)(  
CFXSSSquaresofSumTotal i )()(
2  
CFntotalTreatmentSSSquaresofSumTreatment ))(()( 2  
CFntotalionConcentratSSSquaresofSumionConcentrat ))(()( 2  
1)( nDFfreedomofDegreesTreatment  
1)( nDFfreedomofDegreesionConcentrat  
1)( NDFfreedomofDegreesTotal  
DF
SS
SquareMean  
 
Where 
 n = number of observations per treatment/concentration 
N= number of observations in total 
 
Table B10 Two way ANOVA table for the effect of fluorescence labelling on 
toxicity 
Source DF SS MS F P 
Treatment 2 614028.2 307014.1 31.76738331 0.0035 
Concentration 2 119101.6 59550.78 6.161841803 0.06 
Error 4 38657.78 9664.444    
Total 8 771787.6      
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Table B11 Two way ANOVA table for the effect of physicochemical effects on 
toxicity 
Source DF SS MS F P 
Treatment 2 0.000574 0.000287 7.704172876 0.0425 
Concentration 2 0.000591 0.000295 7.923248882 0.0406 
Error 4 0.000149 3.73E-05    
Total 8 0.001314      
            
 
Table B12 Two way ANOVA table for the effectiveness of the conjugate data 
Source DF SS MS F P 
Treatment 2 0.017393 0.008697 78.5237 0.000617 
Concentration 2 0.000225 0.000113 1.015801 0.4 
Error 4 0.000443 0.000111    
Total 8 0.018061      
            
 
